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Abstract 
 
 
Children with chronic kidney disease (CKD) have significantly increased 
cardiovascular mortality. The reasons for this remain unclear, as the 
pathological effects of renal disease have not been well characterised. This is 
because current methods of assessment like echocardiography have 
significant limitations. Cardiovascular magnetic resonance imaging (CMR) is 
the reference standard method for cardiovascular assessment. Therefore, the 
aim of this thesis is to investigate the utility of CMR for the cardiovascular 
assessment of children with renal disease.  
 
Three separate studies were carried out to comprehensively characterise the 
cardiovascular phenotype in the following groups: pre-dialysis CKD, dialysis 
dependent CKD and renovascular hypertension. They were compared with a 
control group of healthy and essential hypertension children. All subjects 
underwent a CMR study with non-invasive blood pressure measurements. 
The protocol included novel sequences that assessed diastolic function and 
myocardial velocity, in addition to conventional measures. Between group 
ANOVA comparisons were performed as described; mild, moderate and 
severe pre-dialysis CKD (n=100) versus healthy children (n=20), 
Haemodialysis (n=9), peritoneal dialysis (n=8), pre-dialysis CKD stage 5 
(n=10) versus healthy children (n=10), and renovascular hypertension (n=15), 
essential hypertension (n=15) versus healthy children (n=15).  
 
 5 
Blood pressure and systemic vascular resistance (SVR) were elevated while 
total arterial compliance was normal in all renal patients. There was also 
evidence of left ventricular remodelling without hypertrophy in pre-dialysis and 
renovascular children. Diastolic dysfunction was present in all renal patients. 
Systolic myocardial velocity was impaired only in CKD but not in renovascular 
hypertension.  
 
In conclusion, CMR offers valuable insight into the cardiovascular 
characteristics of renal disease. Hypertension in renal disease is 
predominantly secondary to elevated SVR. Diastolic impairment preceded left 
ventricular hypertrophy. Sub-clinical systolic dysfunction was also present in 
renal dysfunction. Further studies are warranted to investigate the future role 
of CMR for cardiovascular risk assessment in paediatric renal disease.  
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1 Introduction 
 
Chronic kidney disease (CKD) is associated with a significantly higher 
mortality risk in adults (1). This risk increases as renal function deteriorates 
(Figure 1.1). Cardiovascular (CV) mortality is one of the leading causes of 
death in end-stage renal disease (2). This is because CV risk factors like 
essential hypertension and diabetes mellitus are common co-morbidities in 
the adult population. In fact, they are the two main causes of renal disease in 
adults (3) and are independently associated with adverse long-term CV 
effects. However, the confounding effect of these conditions has made it 
difficult to study the pathophysiological impact of renal disease on the CV 
system. While epidemiological studies have clearly demonstrated an 
independent link between CKD and CV risk (1), the mechanistic relationship 
between CKD and CV effects remain poorly understood.  
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Figure 1.1: Graphs showing (a) age-standardised mortality rate and (b) 
cardiovascular events. (Reproduced with permission, Go et al. (1). 
Copyright Massachusetts Medical Society). 
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1.1 Paediatric renal disease 
 
Paediatric CKD represents a unique opportunity to study the independent 
effects of renal disease on the CV system. Although CV mortality is also a 
major cause of death in children (4), the diagnosis of CKD is not usually 
preceded by a long history of traditional CV risk factors, as is commonly the 
case in adults. This is because the aetiology of paediatric CKD is markedly 
different to adults. The main causes of renal disease in children are congenital 
abnormalities of the kidney and urinary tract (CAKUT), glomerulonephritis and 
hereditary nephropathy (5). These three causes together, account for 72% of 
the paediatric CKD population (Figure 1.2).  
 
 
 
 
Figure 1.2: Three main causes of chronic renal disease in children 
(North American Pediatric Renal Transplant Cooperative Study, 
NAPRTCS, 2008 Annual Report) (5). 
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Paediatric renal disease may also be associated with CV risk factors. Both 
hypertension and dyslipidaemia can be found in up to 50% of children with 
CKD (4). However, unlike adults, the premature development of CV risk in 
children is likely to be a direct result of the pathological changes to 
biochemistry, cardiac and vascular function brought on by chronic renal 
disease itself (6). 
 
Nonetheless, there is seldom a history of chronic exposure to CV risk factors 
in children. Given that CV risk remains elevated in children, this is further 
evidence of the independent effect of CKD on the CV system. Indeed, CV 
abnormalities in children are very similar to that of adults (6). Hence, 
paediatric CKD may be regarded as a relatively “pure” disease substrate, 
without the confounding effect of long-standing CV co-morbidities. Studying 
the CV effects of CKD in children may offer valuable insight into the disease 
process.  
 
1.2 Mechanisms of cardiorenal syndrome 
 
The complex interaction between kidney and heart involve a multitude of 
different neurohumoral and immune-mediated pathways. The relationship 
between heart and renal failure has been categorised into five different types 
of cardiorenal syndrome. This project is primarily concerned with studying the 
effects of chronic renal disease on the cardiovascular system, namely 
cardiorenal syndrome type 4 (Figure 1.3).  
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Figure 1.3: Overview of different mechanisms of Cardiorenal Syndrome 
Type 4 (Reproduced with permission Ronco et al. (7)) 
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Chronic kidney disease is associated with structural and functional changes to 
the myocardium and vasculature (7). These are thought to be primarily due to 
the adverse effects of progressive renal dysfunction and dialysis. The 
pathophysiological mechanisms are summarised in Figure 1.3 
 
Renal dysfunction leads to accumulation of the uraemic milieu and fluid and is 
associated with complications such as mineral bone disease and anaemia. 
Uraemic toxins contribute to the development of diffuse interstitial fibrosis and 
microvascular disease in the myocardium (8). Myocardial fibrosis leads to left 
ventricular diastolic dysfunction and arrhythmias and may be a contributory 
factor to high rates of sudden cardiac death in end stage renal disease (9). 
Patients with uraemia related microvascular disease have decreased 
coronary flow reserve with abnormal coronary vasculature and are at risk of 
ischaemic myocardial injury (8).  
 
In addition to uraemia, abnormal calcium and phosphate metabolism can also 
cause atherosclerosis (accelerated coronary atheroma development and 
associated ischaemic risk) and arteriosclerosis (premature calcification of 
intima media of aorta leading to increased aortic stiffness and hypertension) 
(6). Chronic fluid overload and anaemia have neurohumoral effects that lead 
to adverse cardiac remodelling. Furthermore, dialysis confers additional risks. 
It is associated with a chronic inflammation state that promotes endothelial 
dysfunction. Haemodialysis has also been shown to cause repeated episodes 
of subclinical myocardial ischaemia that eventually lead to heart failure (7).  
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Regardless of the mechanism, CV abnormalities may be an early indication of 
increased CV risk. Early intervention may be beneficial in these patients. 
However, identifying them early is difficult, as the cardiovascular changes in 
CKD are often subtle.  
 
1.3 Vascular effects of renal dysfunction 
 
Hypertension is common in paediatric CKD and may in part account for the 
adverse myocardial effects described in the later sections (6). The under 
diagnosis (10) and under treatment (11) of hypertension that is frequently 
observed in clinical practice further contributes to CV risk.  
 
Hypertension is present in almost half of all children in pre-dialysis CKD, with 
increasing prevalence in the later stages of CKD (12). It can be found in up to 
75% of the dialysis population (6). Although the cause of hypertension in CKD 
is multifactorial (13), abnormal vascular structure and function is thought to be 
an important determinant (Figure 1.4). 
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Figure 1.4: Multifactorial causes of hypertension in Chronic Kidney 
Disease (Reproduced with permission from Hadtstein et al. (13)) 
Abbreviations: BP= blood pressure, CO= cardiac output, TPR= total 
peripheral resistance, PTH= parathyroid hormone, Na= sodium. 
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The key changes to vascular structure in paediatric CKD are atherosclerotic 
and arteriosclerotic processes, leading to vessel wall remodelling and 
calcification resulting in arterial wall thickening and stiffness (6). These 
changes have been documented early in the disease process in mild to 
moderate CKD with minimal haemodynamic consequence (14). They become 
markedly abnormal in end-stage renal failure, particularly in the dialysis 
population. The consequence is significant reduction in arterial compliance 
and distensibility, which in turn contributes to an increased arterial afterload 
and high blood pressure (BP) (6).  
 
Pulse wave velocity (PWV) and carotid artery intima-media wall thickness 
(cIMT), both clinically validated markers of arterial stiffness and vascular 
structural changes respectively, are commonly used for vascular assessment. 
However, there are other haemodynamic features in CKD such as elevated 
circulating volume and vascular resistance that may be physiologically 
important but are not reflected in either of these indices (Figure 1.4). They 
require different methods to measure, are difficult to assess accurately and 
are seldom measured. At present, comprehensive assessment of vascular 
function will therefore require multiple imaging modalities, which is time-
consuming and impractical to perform. Because quantifying components of 
vascular load and myocardial function simultaneously can be challenging with 
conventional methods, it is difficult to determine their relative contribution to 
hypertension and studying its impact on myocardial function. 
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1.4 Myocardial effects of renal dysfunction 
 
The most common finding in CKD is concentric left ventricular hypertrophy 
(LVH). It is a maladaptive ventricular response to increased arterial afterload 
commonly seen in hypertension (15). As hypertension is common in CKD, 
LVH is also prevalent and can be found in up to 17-50% of pre-dialysis and 
80-90% of dialysis children (16). Left ventricular hypertrophy is associated 
with worse long term outcomes in adults (17) and its presence indicate the 
need for further BP optimisation (18). Indeed, good BP control may promote 
regression of LVH in paediatric CKD (19).  
 
In addition, other LV geometric abnormalities such as concentric remodelling 
and eccentric LVH are commonly seen in paediatric CKD (20) and may also 
be associated with adverse CV risk (21). However, the reasons for different 
remodelling responses in this population remain unclear. Furthermore, 
accurate diagnosis of LVH is challenging due to limitations associated with 
two-dimensional echocardiography (ECHO), which is the standard method 
used in clinical practice (22). This will be further discussed in subsequent 
sections.  
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Global left ventricular (LV) function as measured by ejection fraction (EF) is 
frequently preserved in paediatric CKD (23, 24). Despite that, subtle LV 
abnormalities such as diastolic impairment may be present in children with 
CKD (25-27). The evidence for systolic impairment is more equivocal. Several 
small studies have documented a reduction in longitudinal myocardial systolic 
velocities using tissue Doppler ECHO (26, 28). On the other hand, a larger 
study found preserved longitudinal systolic strain but impairment in radial and 
circumferential mechanics (23). Unfortunately, all previous studies have used 
ECHO (which has well-known methodological limitations, as elaborated later 
in the chapter) and few have involved large study numbers. Furthermore, no 
single study has ever undertaken a comprehensive cardiac assessment in this 
population. This has undoubtedly contributed to the lack of consistency 
between studies. Consequently, myocardial function in CKD remains poorly 
defined. 
 
1.5 Cardiovascular effects of renovascular disease 
 
The CV effects outlined above arise from the pathophysiological 
consequences associated with kidney dysfunction, and are mainly the result 
of renal parenchymal disease (5). Indeed, parenchymal disease is the final 
common pathway for end stage renal failure. However, it is by no means the 
only way that kidney disease can affect the CV system. Disorders affecting 
renal vasculature can also cause profound CV changes through mechanisms 
different to those outlined previously.  
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In adults, atherosclerotic renal artery stenosis is the main cause of 
renovascular disease. It is also an important cause of renal failure, accounting 
for up to 14% of dialysis patients over 50 years of age (29). Its prevalence 
increases with age and is closely associated with other CV co-morbidities 
such as essential hypertension, diabetes, peripheral vascular disease and 
coronary artery disease (30). It is also associated with LVH, diastolic 
dysfunction and heart failure. It is therefore unsurprising that renovascular 
disease in adults confers an increased CV mortality risk (31). 
 
Renovascular disease is less common in children compared to adults. 
However, it is important as it accounts for 10% of the paediatric hypertension 
population (32). The causes of renal artery stenosis in children are markedly 
different to adults. In children, fibromuscular dysplasia and Takayasu’s 
arteritis are the two most common causes (33). Other causes include 
syndromic related conditions such as neurofibromatosis type 1 and tuberous 
sclerosis, other vasculitides e.g. Kawasaki disease and polyarteritis nodosa, 
and external compression due to tumours like neuroblastoma. 
 
Hypertension is a cardinal feature in children with renal artery stenosis. The 
CV risk factors typically seen in the adult population are seldom encountered 
in paediatric renovascular disease (32). Renal artery stenosis in children is 
almost always treatable and in some instances hypertension may even be 
completely reversible (33). Because of this, the CV risk is not believed to be 
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significant. However, there have been no studies on long-term CV effects of 
paediatric renovascular disease. Thus, CV effects of renal artery stenosis are 
unknown, as it has never been documented in children.  
 
1.6 Cardiovascular risk assessment in renal disease 
 
While there has been some improvements in mortality over the past decade, it 
remains significantly elevated in CKD (4). Cardiovascular events continue to 
be a major contributor to that risk (4). Clearly, any effort to improve mortality 
and morbidity will require intervention measures targeting CKD children at 
increased CV risk. However, as previously mentioned, one of the difficulties 
associated with this approach is the challenge of accurately identifying high-
risk patients early on using imaging biomarkers. At present, 
echocardiography, applanation tonometry or oscillometry and high-resolution 
ultrasound for cardiac assessment, aortic pulse wave velocity and carotid 
intimal-media thickness measurement respectively, have been used in the 
clinical assessment of these children. Although these techniques have been 
able to detect abnormal changes, they also have significant limitations.  
 
1.7 Limitations of two-dimensional echocardiography  
 
Echocardiography is the standard imaging modality used in the CV 
assessment of paediatric CKD. The main advantages are that it is widely 
available, cheap and can be performed quickly. Because ECHO is non-
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invasive and does not require any contrast, it is usually well tolerated by 
children.  
 
Apart from assessment of LV structure and global function, it can also detect 
subtle changes to cardiac function. Diastolic function is assessed with 
measures of cardiac timings and mitral inflow such as like isovolumic 
relaxation time (IRT) and ratio of early (E) to late (A) mitral diastolic flow 
velocity (E/A). Measurements of myocardial tissue velocity may also be 
obtained using tissue Doppler (34). Although tissue Doppler can only measure 
longitudinal function, changes in longitudinal velocities are sensitive markers 
of myocardial impairment and may precede the deterioration in global function 
(35).  
 
More recently, the strain imaging via speckle tracking in ECHO has been used 
to quantify the myocardial systolic strain. It is able to assess the main 
components of systolic mechanics namely longitudinal, radial and 
circumferential function and is a sensitive marker of myocardial abnormality 
(36). 
 
Despite its strengths, ECHO has several important limitations. Two-
dimensional ECHO relies on geometrical assumptions to calculate 
haemodynamic parameters such as cardiac output. These assumptions are 
often not valid and contribute to inaccuracies in haemodynamic measures 
(37). Thus, ECHO is seldom used to assess vascular function in clinical 
practice.  
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Similarly, ECHO measures of LV mass are not accurate as it is also based on 
assumptions of LV geometry and is susceptible to high inter- and intra-
observer variability (38). Previous studies comparing cardiovascular magnetic 
resonance (CMR) measurement of LV mass with ECHO assessment, found 
that ECHO consistently overestimated mass measurements (39). 
Echocardiography also suffers from poor reproducibility of its measurements 
(22). This may be due to poor spatial resolution in ECHO, which is further 
compounded by poor echogenic windows in some individuals. In addition, the 
intrinsic nature of techniques such as tissue Doppler (e.g. angle dependence) 
and strain imaging (e.g. reliance on good spatial resolution) are susceptible to 
inaccurate measurements and high observer variability (40, 41). This may be 
the reason for inconsistency in tissue Doppler and strain findings between 
different studies mentioned above (23, 26, 28).  
 
1.8 Limitations of current methods of vascular assessment  
 
Many different non-invasive methods of vascular assessment exist and have 
been used in research. Of these, pulse wave velocity and carotid intimal 
media thickness (cIMT) measurements are most widely used in the clinical 
setting. This is because both methods have been validated with established 
reference values and been shown to have prognostic significance in adults 
(42).  
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Pulse wave velocity is a measure of aortic stiffness. The detection of pulse 
waves at well-defined sampling sites (carotid and femoral arteries) can be 
performed using applanation tonometry, oscillometry or ultrasound methods. 
The distance between the sampling sites is then divided by the transit time 
(time of travel of the PW from carotid to femoral) to obtain the PWV (43). It 
has been shown to be increased in CKD children and is associated with 
reduced aortic compliance (6). However, assessment of PWV in children has 
several difficulties. The measurements can be inaccurate due to technical 
difficulty of recording pulse waves with different devices (43). The distance 
between sampling sites cannot be measured accurately without a CMR scan. 
Thus, it is often estimated using different methodologies and this further 
contributes to inaccuracy (42). Pulse wave velocity is also highly dependent 
on age and body dimensions, which makes it difficult to evaluate and compare 
in children (44).  
 
Carotid intimal-media thickness is recorded using high-resolution ultrasound 
and is a measure of the structural changes to the carotid artery (42). 
Increased cIMT has been found in both pre-dialysis and dialysis CKD children 
(14, 45). It has also been shown to correlate with a higher risk of mortality and 
coronary events in dialysis adults (46). Because of its association with high 
BP and increased LV mass, cIMT is thought to be a marker of arterial stiffness 
(42). However, it is important to point out that cIMT is merely a surrogate of 
arterial stiffness. Studies have shown that although cIMT is increased in pre-
dialysis children, the arterial compliance and distensibility remains normal 
(14). This suggests that cIMT poorly reflects the haemodynamic consequence 
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of vascular remodelling in CKD. Both PWV and cIMT are not ideal indicators 
of the haemodynamic effects of vascular remodelling. Thus, there is a need 
for better methods of assessing for vascular and myocardial abnormalities in 
paediatric CKD.  
 
1.9 CMR – a tool for cardiovascular assessment in CKD 
 
Cardiac magnetic resonance imaging is the reference method for CV 
assessment. Nonetheless, conventional CMR suffers from a major limitation. 
It is unable to detect sub-clinical myocardial impairment such as diastolic 
dysfunction. This is particularly important in the paediatric CKD population 
where sub-clinical changes to cardiac mechanics precede the deterioration in 
global function. Undoubtedly, this has been an impediment to the clinical use 
of CMR as a cardiovascular assessment tool in this population. However, 
recent innovations in CMR technology may overcome these conventional 
limitations. This will be further described in chapter 2.  
 
If CMR may detect the subtle CV changes in the paediatric CKD population, 
its utility as a clinical tool may be considerable. It will avoid the inconvenience 
and cost of multiple investigations. Indeed, the ability to simultaneously 
assess cardiac and vascular function is one of the greater strengths of CMR. 
It may also provide greater insight into the complex relationship between 
vascular remodelling, myocardial function and renal severity.  
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2 Application of novel CMR sequences in paediatric 
renal disease 
 
Cardiovascular magnetic resonance is a valuable clinical tool for the 
assessment of cardiovascular disease. Measurements of conventional 
myocardial indices by CMR are superior to two-dimensional ECHO. This is 
because cardiac magnetic resonance imaging (MRI) does not rely on 
geometric assumptions for LV mass and volume calculations, unlike ECHO. 
Myocardial borders are usually clear enough for direct tracing of the LV. 
Hence, inter- and intra-observer variability is superior in CMR because of 
better spatial resolution (22).  
 
In addition, cardiac output and stroke volume can be measured accurately 
and correlates well with invasive measurements (47, 48). Thus, systemic 
vasculature can be characterised by quantifying the pulsatile and non-
pulsatile components of systemic afterload, namely, total arterial compliance 
(TAC), systemic vascular resistance (SVR) (49) and regional vascular 
properties such as aortic strain and distensibility indices in the ascending 
aorta (50). Furthermore, CMR does not involve ionising radiation, is non-
invasive and can be performed even without using magnetic resonance 
contrast. This is important as contrast media is contra-indicated in end-stage 
renal disease due to the risk of nephrogenic systemic fibrosis (51).  
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As previously mentioned, the ability to detect subclinical myocardial 
impairment is essential for early disease detection and intervention. This is 
especially relevant in the paediatric CKD population where abnormalities are 
frequently subtle. Thus, in order for CMR to be an effective cardiovascular 
assessment tool, it must be able to accurately assess conventional 
cardiovascular indices as well as other indicators of early myocardial 
dysfunction. It is also important that the CMR study protocol is optimised for 
these children as this will contribute to improved scan quality by promoting 
better compliance with the investigation. The novel CMR sequences used in 
this study were specifically selected to optimise the utility of CMR in this 
population.  
 
In this chapter, I will give an overview of the novel CMR sequences used to 
detect sub-clinical abnormalities and how it is used to optimise cardiovascular 
assessment in paediatric CKD. It is beyond the scope of this thesis to discuss 
magnetic resonance physics in great detail. However, I will briefly discuss the 
basic concepts in magnetic resonance physics of image acquisition in order to 
provide the context to the clinical application of these sequences in this 
project.  
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2.1 Basics of CMR image acquisition 
 
Magnetic resonance imaging comprise of signals that arise from the hydrogen 
nuclei in the body precessing (52). In the presence of a strong MRI magnetic 
field, the hydrogen protons, which act as multiple individual magnets, “line up” 
and precess at the Larmor frequency (ω), which is mathematically defined by 
ω = γ x B0, where γ=gyromagnetic constant (specific for the nuclei being 
imaged, normally hydrogen) and B0=magnetic field strength. The transmission 
of a radiofrequency (RF) pulse at the Larmor frequency flips the net 
magnetisation vector into the transverse plane and is the basis of the 
magnetic resonance (MR) signal. The RF pulse also causes the nuclei to 
become aligned and as they continue to precess, the net magnetisation 
induces a small electrical current, which is subsequently detected by the 
receiver coils. In effect, this is a demonstration of Faraday’s law of induction; 
voltage in an adjacent conductor can be induced by a changing magnetic 
field. The MR signal is recorded with receiver coils able to detect magnetic 
flux in two orthogonal directions. The resulting MR signal is complex in nature 
and comprises of two parts, namely, a ‘real’ and ‘imaginary’ component. It can 
also be expressed as a vector with a magnitude and phase component 
(Figure 2.1).   
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Figure 2.1: Magnetic resonance (MR) signal: Represented as complex 
numbers consisting of real and imaginary numbers or as magnitude and 
phase components. X=Total MR signal at a point in K-space, 
I(X)=Imaginary component of MR signal, and R(X)= Real component of 
MR signal 
 
2.1.1 Slice selection 
 
The total MR signal detected is a vectoral sum of all individual signals emitted 
by the hydrogen protons in the body. In order to obtain a meaningful image, a 
method of localising each individual signal is necessary. By altering the 
magnetic field, it is possible to vary the magnetic strength according to spatial 
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position. Applying a magnetic gradient along the length of the subject (z-axis) 
in turn leads to variation in proton precession frequency across space. Thus, 
by delivering RF pulse at a resonance frequency that corresponds with the 
target location, signal acquisition can be restricted to an area of interest 
(slice).  
 
2.1.2 Spatial localisation 
 
Signal localisation within the selected slice, in the xy-plane, requires 
resolution of signals in the x- and y- axes. This is performed using frequency 
and phase encoding. Similar to slice selection, frequency encoding applies an 
additional magnetic field gradient in one axis  (e.g. x-axis) in the xy-plane to 
create a gradient of precession frequencies corresponding to location. The 
total MR signal from the slice, like all oscillating signals, is a composite of 
many sine and cosine waves with different frequencies. Consequently, a 
complex mathematical method known as Fourier transformation can be used 
to breakdown the total signal into its constituent frequency components. This 
is expressed as amplitude for each frequency, which corresponds to intensity 
at each x-axis position. 
 
Phase encoding involves the manipulation of magnetic gradients in an 
orthogonal direction (e.g. y-axis) to induce a shift in the phase of the MR 
signal, such that phase shifts vary along the y-axis. The MR sequence is 
repeated and signal is measured for many different phase encoding gradients. 
Each successive phase shift of the signal is identical to successive 
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measurements of the same signal over time. Thus, the rate of phase shifts is 
itself a frequency that can also be subjected to Fourier transformation to 
determine the amplitude associated with each phase shift, in order to obtain 
intensity for each y-axis position.  
 
Therefore, each pixel of the image slice has a distinct phase and frequency 
combination and two-dimensional Fourier transformation is used to obtain the 
image.  
 
2.1.3 Multi-phase acquisition in cine imaging 
 
In cine imaging, an image is obtained for each cardiac phase and all the 
images (ideally, an image representing a phase in the cardiac cycle) are 
combined to produce a multi-frame cine that captures cardiac motion. As 
such, MR signal acquisition needs to be synchronised to the cardiac cycle in a 
process known as cardiac gating. There are two types of gating, prospective 
and retrospective.  
 
In prospective gating, the electrocardiographic (ECG) tracing is monitored and 
R wave detection is used to trigger the beginning of data acquisition. For the 
purposes of this discussion, ‘acquisition window’ refers to the duration within 
the R-R interval where data acquisition occurs. This usually ends well before 
the next R wave begins to allow a time window (trigger window) when the 
scanner is searching for the next valid R wave. Therefore, trigger windows are 
a necessary feature to accommodate normal heart rate variability. However, it 
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means that no data is collected in late diastole, which is a recognised 
drawback in prospective gating. 
 
Data acquisition is typically completed over several cardiac cycles as one R-R 
interval is never enough time to acquire all the data required to construct an 
image for each cardiac phase. In order to create an image for each cardiac 
phase (i.e. a single frame in a multi-frame cine), the data acquired in the 
acquisition window can be categorised into groups known as ‘segments’, 
where a segment represents the data acquired for each particular cardiac 
phase. Thus, all the data from each segment (acquired over several R-R 
intervals) are collated together to produce an image for each frame of the 
cine. All the frames are complied together to produce a multi-frame cine in 
order to achieve an accurate depiction of cardiac motion. 
 
In retrospective gating, ECG data and MR signal are simultaneously recorded 
in a continuous fashion, over several heartbeats. Based on the number of 
cardiac phases required (determined by the operator) for the cine, the data is 
interpolated at a time point corresponding to each cardiac phase. This is then 
collated to form a cine. The key advantage is that information is collected from 
the entire cardiac cycle and retrospective sequences provide a more complete 
representation of all phases in the cardiac cycle. 
 
Another important advantage of cardiac gating is that it enables the avoidance 
of cardiac motion related artefacts.  
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2.1.4 K-space filling and parallel imaging 
 
To briefly summarise, in conventional Cartesian MRI, the sequence of events 
leading to generation of an MR image is as follows: Transmission of 
radiofrequency pulse, slice selection gradient applied, frequency encoding 
gradient applied, phase encoding gradient applied, followed by readout (i.e. 
measurement of MR signal). This entire sequence is then repeated numerous 
times with different phase encoding gradients. The multitude of MR signals is 
collected and stored in a frequency space known as K-space. Each line in K-
space represents a phase encoding step. Hence, K-space is an array of raw 
data from the digitalised MR signals arranged according to spatial frequencies 
of the actual image. 
 
In theory, the entire K-space must be filled in order to generate a complete 
image. The most common method of filling K-space is the Cartesian method, 
which is the rectilinear filling of K-space, i.e. line by line (Figure 2.2). The 
benefits of the Cartesian method are that it relies on a simple gradient design, 
data is uniformly sampled and can be reconstructed using fast Fourier 
transformation, swiftly and easily (53). However, it is relatively time consuming 
which means that scan time may be prolonged. As such, many different 
methods have been employed to reduce acquisition time. As it is beyond the 
scope of this thesis to describe all of them, discussion will be restricted to the 
two main techniques used in this study, namely, efficient K-space filling 
methods and parallel imaging.  
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Non-cartesian methods of K-space filling such as echo-planar, radial or spiral 
trajectories are more efficient and have been used to increase acquisition 
speed (Figure 2.2). In particular, the spiral trajectory is thought to be one of 
the most time efficient ways to fill K-space (53). These methods have been 
used in the novel sequences in this study and are outlined in later sections.  
 
Parallel imaging is also another technique commonly used to reduce 
acquisition time (52). The undersampling of K space reduces acquisition time 
but results in aliasing artefacts, which must be removed for the images to be 
clinically useful. Parallel imaging is the use of a mathematical algorithm to 
mitigate these artefacts by utilising additional spatial information provided by 
the receiver coils. Multiple receiver coils detect the MR signals simultaneously 
(in ‘parallel’). As each coil has a different distance from the imaged object, 
there is varying intensity in the detected signals in each coil, which is relative 
to its distance from the object (stronger signals when closer in proximity). This 
information is used to help with spatial localisation of the signal. This helps to 
shorten acquisition time by reducing the number of phase encoding steps 
required.  Sensitivity encoding (SENSE) is one of the most commonly used 
methods in parallel imaging (54). SENSE is a system of equations that 
calculate the unaliased pixel data using information from coil sensitivities, 
gradient encoding, and the acquired aliased pixel. This method has been 
used in the sequences described below. 
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Figure 2.2 Different methods of K-space filling: a. Cartesian or 
Rectilinear method - line by line filling of K-space, b. Echo-planar 
method - similar to rectilinear filling except each readout includes 
multiple lines in K-space, c. Radial trajectory, d. Spiral trajectory. 
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2.1.5 Phase contrast Imaging 
 
Phase contrast MR (PCMR) imaging is a technique used to measure blood 
flow (52). When a bipolar gradient is applied to a stationary proton (i.e. a 
stationary magnetic spin), there is no net change in the phase component of 
the MR signal (Figure 2.1). However, when such a gradient is applied to a 
moving hydrogen proton (i.e. moving blood), it will display a net change in its 
phase that is proportional to the velocity of the proton (Figure 2.3). The use of 
phase measurements to estimate blood flow velocity is the principle behind 
PCMR. 
 
 
 
Figure 2.3: Bipolar phase encoding gradient results in a net phase shift 
in moving protons. 
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The bipolar gradient strength can be altered to assign a maximum velocity 
(expected in the vessel of interest) to correspond to a maximum phase shift of 
180 degrees. This process is known as velocity encoding (VENC) and is 
determined by the operator before running the sequence. Typically, each line 
in K-space is acquired twice with a different VENC; one with velocity-
compensated gradients (i.e. with a VENC of zero) and the other with velocity-
encoded gradients (i.e. with the expected VENC). The final phase image is 
formed from the subtraction of the velocity-compensated data from the 
velocity-encoded data, in order to subtract out these background phase shift. 
This process is necessary as it allows the cancellation of potential artefacts 
from background phase shifts arising from magnetic field homogeneities.  
 
Flow is most commonly measured in the through-plane, but can be measured 
in any direction. The PCMR sequence typically produces a phase image 
(where blood or tissue velocity is encoded in each voxel) and the 
corresponding magnitude image (which depicts the anatomical structures). 
Blood flow velocity is measured by segmentation of the region of interest on 
the magnitude image (Figure 2.4). 
 
2.2 Optimising cardiac flow assessment in children  
 
The main drawback of conventional (Cartesian) PCMR is the slow speed of 
acquisition (55). One of the reasons for this is the need to acquire each line in 
K-space twice with different VENCs, as previously explained. Unsurprisingly, 
image acquisition using a free breathing sequence is prolonged and this 
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creates lengthy MRI scans that are poorly tolerated in the paediatric 
population. Spatial and temporal resolution may be reduced to increase the 
speed of acquisition such that data can be acquired in a breathold. However, 
often the breathholds are still greater than 15 seconds and remain too long for 
children to perform. Furthermore, the reduction in spatiotemporal resolution is 
not ideal for the clinical assessment in children who have higher heart rates 
and smaller vascular structures.    
 
 
 
 
Figure 2.4: Example of Magnitude and Phase images from a PCMR 
sequence acquired in the proximal ascending aorta 
 
In order to accurately assess flow in children, this department created a novel 
PCMR sequence with a high spatiotemporal resolution and a short breathold. 
This was achieved using efficient K-space filling via spiral trajectories and 
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undersampling combined with SENSE, a parallel imaging reconstruction 
technique. This technique has been shown to reliably measure flow in children 
with congenital heart disease (55). This sequence will be used in this study 
(described further in Chapter 3).  
 
2.3 Optimising ventricular assessment in children  
 
Assessment of cardiac volume and structure involves taking numerous 
sequential cine images in a stack along the length of the ventricles. Motion 
artefacts caused by cardiorespiratory movement are mitigated by 
breathholding during acquisition and electrocardiographic gating. However, as 
previously mentioned, conventional Cartesian CMR sequences are slow. This 
results in multiple long breatholds that are poorly tolerated by children and 
contributes to prolonged scan times and sub-optimal images (56).  
 
Real-time cine imaging is one way to overcome these problems. 
Conventionally, it uses the echo-planar trajectory (Figure 2.2), which is 
another efficient K-space filling technique; a rectilinear method of filling K-
space similar to Cartesian method, whereby each readout fills several lines in 
K-space. This is combined with reduction in the number of phase encoding 
lines in K-space to facilitate rapid acquisition of multiple single shot images to 
create the cine. Consequently, real time imaging can be performed during free 
breathing. However, its accuracy may be limited by a significantly lower 
spatiotemporal resolution. 
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This department developed a superior real-time cine imaging sequence with 
good spatiotemporal resolution. This was achieved by combining efficient 
radial K-space filling, K-space undersampling and a parallel imaging 
technique known as k-space and time sensitivity encoding (K-T SENSE). The 
K-T SENSE is a more robust reconstruction algorithm, which uses 
spatiotemporal correlations in addition to coil sensitivities (compared to 
SENSE which only uses coil sensitivities). This allows a greater degree of 
undersampling to be performed and facilitates further acceleration in 
acquisition. This sequence has been shown to be able to accurately quantify 
ventricular volumes and functions in children with congenital heart disease 
(56) and has been used in this study. 
 
2.4 Measuring cardiac timings 
 
The role of CMR as a tool to detect early disease is dependent on its ability to 
detect subtle cardiac changes. Assessment of diastolic function is important, 
as diastolic dysfunction may be a feature of early cardiac disease. In 
echocardiography, the measurement of cardiac timings such as isovolumic 
relaxation time and early (E wave) and late transmitral flow (A wave) to obtain 
the E/A ratio, are commonly used indices. Indeed, diastolic indices have been 
shown to be abnormal in the paediatric CKD population (27). Unfortunately, 
these indices are not measured in standard clinical CMR studies. 
 
Conventional PCMR may be used to measure cardiac timings and transmitral 
flow. However, its utility is severely limited by cardiac gating (used in 
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conventional PCMR sequences) as it results in alterations in ventricular flow 
patterns flow due to interbeat variability in heart rate and stroke volume (57). 
This may affect the accuracy of cardiac timing measurements. Furthermore, in 
order to achieve an adequately high temporal resolution to measure cardiac 
timings, long acquisition times are required and may not be practical in the 
clinical setting.  
 
An accelerated real time spiral PCMR sequence may be achieved by 
combining efficient K-space filling with parallel imaging like SENSE (57). 
Although this will not require cardiac gating and avoids the aforementioned 
problem, temporal resolution remains insufficient for a reliable measurement 
of cardiac timings (which requires high temporal resolution, <15ms). 
 
In order to overcome these challenges, this department developed a highly 
accelerated PCMR sequence by combining parallel imaging reconstruction 
algorithm with temporal acceleration to allow a higher degree of 
undersampling, namely “unaliasing by fourier-encoding the overlaps using the 
temporal dimension” (UNFOLD) and SENSE techniques. This was also 
combined with spiral trajectory to achieve a sufficiently high temporal 
resolution. This sequence has been validated against echocardiography and 
been shown to accurately measure cardiac timings (57). It will be used in this 
study to assess diastolic function. 
 
 
 52 
2.5 Alternative methods of myocardial assessment 
 
Sub-clinical changes in myocardial function may be detected using myocardial 
deformation and velocity assessment. Echocardiography has been used to 
demonstrate sub-clinical abnormalities in both domains in paediatric CKD. 
Thus, they may be useful indicators of early cardiac disease. Cardiac MRI 
may also be used to study these domains.  
 
2.5.1 Alternative methods of myocardial assessment in CMR 
 
Feature tracking has attracted some recent attention due to its ease of 
application (58). It is a post-processing method that can be applied to routine 
cine images and does not require additional image acquisition. Displacement 
of myocardial segments is measured by tracking image features through 
sequential cardiac phases to obtain longitudinal, circumferential and radial 
strain. A significant limitation of this technique is the great variability in strain 
values observed between studies, which will inevitably hamper its widespread 
use as a clinical tool.  
 
Cardiovascular MR tagging is a method of superimposing magnetic labels on 
the myocardium using a specific radiofrequency saturation pulse known as 
spatial modulation of magnetization (SPAMM) (58). These ‘tags’ are tracked 
throughout the cardiac cycle to obtain myocardial deformation. It is a validated 
method of measuring strain in CMR. However, its utility is severely limited by 
low spatiotemporal resolution, long acquisition and post-processing times. It 
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also does not provide any information in late diastole due to the problem of 
tag fading (as a result of T1 relaxation).  
 
2.5.2 Measuring myocardial velocity 
 
Magnetic resonance tissue phase mapping (TPM) is a phase contrast MR 
sequence that can measure myocardial velocity (59). Tissue velocity is 
acquired in 3 orthogonal directions (x-, y- and z- plane) and at a sufficient 
spatiotemporal resolution. In a conventional Cartesian TPM sequence, this 
results in a relatively long acquisition time (about 10 minutes long), which 
cannot be performed in a single breathold (59). Consequently, respiratory 
navigation is required to avoid breathing motion artefacts. Respiratory 
navigation is a technique used to limit data acquisition to a part of the 
respiratory cycle (usually in the expiratory phase) to mitigate motion artefacts. 
This is usually done using real-time imaging with a pencil beam excitation to 
measure diaphragmatic motion (52). Thus, prospective cardiac gating is 
required to create a period in the cardiac cycle (usually in diastole) where no 
TPM data acquisition occurs, in order for respiratory navigation to be 
performed. The main problem with this method is that myocardial velocity in a 
part of the cardiac cycle cannot be measured. This significantly limits its ability 
to comprehensively assess diastolic function. 
 
To overcome this limitation, this department implemented a novel self-
navigated retrospectively gated spiral TPM sequence. Self-navigation involves 
reconstructing real-time images from the TPM data collected to create an 
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image-based navigator. Only spiral interleaves acquired in expiration 
(identified with the navigator) are then used for reconstruction of the final TPM 
data. The use of spiral acquisition meant that data acquisition was relatively 
more time efficient than the conventional Cartesian TPM sequence.  The 
average acquisition time is 8.7 min (compared to 10.5 min in a Cartesian TPM 
sequence) (59). This sequence produced a magnitude image and 3 phase 
images (one for x-, y-, and z- directions). Post processing of this data enabled 
the calculation of the longitudinal, radial and circumferential velocities (further 
described in Chapter 3). These data have been validated (59) and used to 
demonstrate subtle abnormalities in diastolic function in pulmonary 
hypertension (60). It will be used in this study to assess for sub-clinical 
systolic and diastolic dysfunction. 
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3 Research objectives 
 
In summary, cardiovascular disease burden is high in children with renal 
disease. The ability to identify high-risk children who will benefit from early 
intervention is key to reducing CV mortality. Better methods of assessment are 
needed to detect CV changes that are often subtle in this population. 
Cardiovascular magnetic resonance imaging using novel sequences may be a 
better alternative.  
 
The aim of this MD project is to investigate the utility of CMR in the CV 
assessment of children with renal disease. As pre-dialysis chronic kidney 
disease is most commonly encountered in clinical practice, this project will 
mainly focus on the comprehensive characterisation of the cardiac and vascular 
phenotype in pre-dialysis paediatric CKD.  
 
In addition, I will also undertake two smaller exploratory studies to investigate 
the utility of CMR in children on dialysis and with renovascular hypertension, in 
order to determine its potential applicability in the wider paediatric renal 
population. These results will form the basis for the conduct of larger studies in 
paediatric dialysis and renovascular hypertension in the future. 
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3.1 Study hypotheses 
 
Separate studies were designed to test each of the following three hypotheses: 
 
1. Cardiovascular abnormalities in paediatric renal disease can be detected 
using CMR and worsens with disease severity.  
 
2. Cardiovascular abnormalities are present in treated paediatric renovascular 
hypertension and are different to essential hypertension patients.  
 
3. Renal replacement therapy has an incremental adverse cardiovascular effect 
in paediatric CKD. 
 
Correspondingly, cardiac MRI was performed on three study groups, namely 
pre-dialysis CKD children, children with renovascular hypertension (without 
renal impairment) and children receiving dialysis, and compared with control 
population.  
 
3.2 Thesis Outline  
 
The clinical context of this project, principles behind the novel MRI sequences 
used, methodology and findings from these three studies are described in the 
following chapters. 
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Chapter 1, 2 and 3 outlined the introduction, novel CMR sequences used in this 
study and research objectives, respectively.  
 
Chapter 4 will describe the methodology employed in all three studies. 
 
Chapter 5 will discuss the vascular findings in pre-dialysis population compared 
with essential hypertension and healthy control population.  
 
Chapter 6 will discuss the myocardial findings in pre-dialysis population 
compared with a healthy control population.  
 
Chapter 7 will discuss cardiovascular findings of the renovascular population 
compared with essential hypertension and healthy control population. 
 
Chapter 8 will discuss cardiovascular findings in the dialysis population 
compared with pre-dialysis and a healthy control population. 
 
Chapter 9 will summarise the findings and reflect on potential future work. 
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4 Methodology 
 
In this chapter, I will discuss the methodology, which have been used 
consistently in all the three studies described in this thesis.  
 
4.1 Personal contribution 
 
For all the studies described in this thesis:  
 I wrote the ethics application, presented it to a national ethics committee 
meeting and successfully got ethics approval at the first sitting 
 I undertook all patient recruitment related activities, including patient 
recruitment and taking assent and consent from all subjects and their 
parents.  
 I reviewed and recorded all relevant details from patients’ notes.  
 I designed the CMR protocol using existing departmental CMR sequences.  
 I personally performed the CMR scan on the majority of subjects. 
 I completed the segmentation and data analysis on all study subjects.   
 
4.2 Study population recruitment  
 
Patient recruitment was carried out from June 2015 to September 2016. The 
CKD, renovascular and essential hypertension patients were recruited from the 
renal clinic and paediatric hypertension clinics at Great Ormond Street Hospital 
(GOSH) respectively. The exclusion criteria for each of the three studies are 
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described in detail in the respective chapters. The medical notes were reviewed 
in all recruited subjects to ensure that they did not fulfil any exclusion criteria. 
Medical history and current medications were recorded and confirmed with 
parents and patients on the day of the study.  
 
Healthy subjects were recruited by advertisements within the hospital. A detailed 
history was taken from the parents of healthy children to ensure there was no 
significant medical history and they were not on any current medications.  
 
4.3 Medical ethics and consent  
 
This study was approved by UK national research ethics service (NRES 
Committee London, London Bridge, REC reference: 15/LO/0213). Suitable 
patients were identified by their clinicians and given initial information about the 
study. Subjects who were interested were subsequently contacted with a 
telephone call and received an information sheet (via email or post) containing 
all the required information. Ample opportunity was provided to patients to ask 
questions before consenting. All subjects were given more than 24 hours to 
consider the study information before consenting to taking part. Informed 
parental consent and patient assent was obtained from all participants.  
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4.4 Protocol 
 
The entire study population underwent the same research protocol. This 
consisted of non-invasive BP measurements and CMR characterisation of 
cardiovascular phenotype as further described in the below section. 
 
4.4.1 Blood pressure measurement 
 
Casual brachial systolic, diastolic and mean arterial blood pressures (SBP, DBP, 
MBP) were measured using a CMR compatible oscillometric 
sphygmomanometer (Datex Ohmeda; General Electric, Boston, USA) in the 
CMR scanner bore. Two BP measurements were taken after the subject had 
been lying in the scanner for at least 10 minutes using an appropriate sized arm 
cuff according to current guidelines (61). The first BP measurement was 
discarded. The second blood pressure measurement was acquired 
simultaneously with CMR assessment of aortic flow. This enabled optimum 
combination of BP and flow data for calculation of vascular indices. Pulse 
pressure (PP) was the difference between SBP and DBP. 
 
The age and sex specific centiles of the BP measurements were recorded using 
the second measurement (61). Subjects with systolic and diastolic BP readings 
<90th percentile were regarded as normotensive while systolic or diastolic BP 
≥90th and <95th percentile were pre-hypertensive and ≥95th percentile were 
hypertensive, as previously defined (61). Controlled and uncontrolled BP was 
defined as prior diagnosis of hypertension (HTN), current use of anti-
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hypertensive medication and (systolic or diastolic) BP <90th percentile or BP 
≥90th percentile respectively. 
 
4.4.2 CMR protocol and image analysis  
 
Imaging was performed on a 1.5T CMR system (Avanto; Siemens Medical 
Solutions, Erlangen, Germany) with vector cardiographic gating. All CMR 
images were processed using in-house plug-ins developed for open-source 
DICOM software OsiriX (62) (the Osirix Foundation, Geneva, Switzerland). All 
images were analyzed by myself, who is a CMR trained cardiologist with 5 years 
of CMR experience. No gadolinium contrast was given. 
 
4.4.3 Left ventricular volumes and mass 
 
Left ventricular volumes were assessed using short axis (SAX) multi-slice free-
breathing real-time radial k-t SENSE steady state free precision sequence (56). 
Scan parameters - FOV: ≈350 mm, matrix: 128×128, voxel size: ≈2.7×2.7×8 
mm, TE/TR: ≈1.1/ ≈2.2 msec, Flip angle: 40°, acceleration factor: 8, temporal 
resolution: ≈36 msec. Endocardial borders of LV were traced manually at end-
diastole and end-systole to evaluate end-diastolic volume (EDV) and end-
systolic volume (ESV). Stroke volume (SV) was obtained by subtracting ESV 
from EDV. All ventricular volumes were indexed to body surface area (BSA). 
Left ventricular function was assessed by ejection fraction (EF = (SV/LVEDV) × 
100).  
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Figure 4.1: Segmentation of (a) LV volumes, (b) tissue phase mapping - 
segmentation on magnitude image, and (c-d) spiral PCMR for LV inflow 
velocity - segmentation on magnitude image. Abbreviations: LV=left 
ventricle, RV=right ventricle, TV=tricuspid valve, MV=mitral valve. 
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Epicardial borders were traced in end-diastole and combined with endocardial 
borders (excluding papillary muscles) to obtain LV mass (LVM) (Figure 4.1). The 
effect of body size on LV mass was controlled in two ways by: i) Indexing to 
height to the power of 2.7 (LVMht2.7) (63) and ii) Dividing LVM by EDV to 
calculate mass volume ratio (MVR) (64).  
 
The right and left atrial areas (RAA & LAA, respectively) were measured by 
tracing the end-diastolic border of the right and left atrium from the 4-chamber 
view (using the same sequence) and indexed to BSA. 
 
4.4.4 Cardiac timing and inflow velocities  
 
Left ventricular outflow tract (LVOT) and mitral inflow velocities were assessed 
with a free-breathing high temporal resolution real-time UNFOLD-SENSE spiral 
phase contrast magnetic resonance sequence. This sequence has previously 
been validated against Doppler ECHO (57). Scan parameters - FOV: ≈450 mm, 
matrix: 128×128, voxel size: ≈3.5×3.5×7 mm, TE/TR: ≈1.97/ ≈7.41 msec, flip 
angle: 20°, VENC: 150m/s, acceleration factor: 10, temporal resolution: ≈15ms. 
The imaging plane was positioned so that both the mitral inflow and LVOT were 
imaged in the short axis (Figure 4.2). 
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Figure 4.2: Acquisition views of difference sequences: (a) Cardiac timings 
and inflow velocities measurement acquired in basal LV SAX view. (b-c,f) 
Myocardial velocities measurement acquired in mid LV SAX view. (d-e) 
Aortic flow measurement acquired above sinotubular junction in 
ascending aorta. Abbreviations: LV=left ventricle, SAX=short axis view. 
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The mitral valve orifice and LVOT were manually segmented to form the 
resultant inflow and outflow curves (Figure 4.1). The velocity curves were 
interpolated to ≈1ms temporal resolution. The mitral inflow mean velocity curve 
consists of an early (E wave) and late diastolic wave (A wave) and were used to 
obtain the peak E and A diastolic velocities. The LV outflow tract velocity curve 
consists of a systolic ejection wave (S wave). The start and end of the S wave, 
the start of the E wave, and the end of the A wave are delineated by the 
horizontal axis intercepts of tangent lines drawn on the ascending and 
descending slopes of the respective waves (57). These are then used to 
calculate the isovolumic relaxation time (IRT), isovolumic contraction time (ICT), 
and ejection time (ET), as seen in Figure 4.3. Myocardial performance index 
(Tei) was calculated as the sum of ICT and IRT divided by ET.  
 
 
 
Figure 4.3: Left ventricular outflow tract (red line) and mitral valve inflow 
(green line) velocity curves against time. (Reproduced with permission 
from Kowalik et al. (6)). Abbreviations: IRT=isovolumic relaxation time, 
ICT=isovolumic contraction time, ET=ejection time, E=Early diastolic 
wave, A=late diastolic wave, and S=systolic wave. 
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4.4.5 Myocardial velocities 
 
Left ventricular myocardial velocities were measured using a free breathing self-
navigated golden-angle spiral tissue phase mapping (TPM) sequence planned 
in the mid LV SAX view (Figure 4.2) (60). Scan parameters - FOV: ≈400 mm, 
matrix: 192×192, voxel size: ≈2.1×2.1×8mm, TE/TR: ≈3.51/ ≈11.7 msec, flip 
angle: 15°, respiratory navigation efficiency: 30%, scan time: ≈7-8min, temporal 
resolution: ≈23 msec.  
 
The epi- and endocardial borders were manually segmented for all phases of 
the cardiac cycle (Figure 4.1). Radial (Rad) velocity was calculated by 
transforming the x and y-direction velocities to an internal polar coordinate 
system using the LV center of mass as a reference point (60). The longitudinal 
(Long) velocity was taken as the z-direction velocity. The ventricular region of 
interest (ROI) was further split into six segments: anterior, anterolateral, 
inferolateral, inferior, inferoseptal, anteroseptal and anterior. Regional velocities 
were calculated by averaging the velocities of each segment within the 
ventricular ROI for each frame. Global radial and longitudinal LV velocities were 
calculated by averaging velocities across the LV for a given direction. The 
magnitude of the peak systolic (S’), early diastolic (E’) and late diastolic (A’) 
velocities was measured from the velocity-time curves (Figure 4.4). E’/A’ ratio 
was the ratio of E’ over A’ velocity for a given direction, radial or longitudinal. 
The longitudinal E/E’ ratio was obtained by dividing E wave mitral E velocity by 
longitudinal peak early diastolic velocity.  
 67 
 
 
 
 
 
Figure 4.4: Example of a radial velocity-time curve in a renal patient. Peak 
systolic (S’), early diastolic (E’) and late diastolic (A’) velocities were 
measured from the curve. 
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4.4.6 Aortic flow and measures of vascular characteristics 
 
Aortic flow assessment was performed using a breath held retrospectively 
gated, spiral SENSE PCMR just above the sinotubular junction (Figure 4.2) (55). 
Scan parameters - FOV: ≈400 mm, matrix: 256×256, voxel size: ≈1.6×1.6×5 
mm, TE/TR: ≈2.1/≈8.0 msec, flip angle: 25°, acceleration factor: 3, breath hold 
time: 4-8sec, temporal resolution: ≈32.0 msec.  
 
The aorta was segmented using a semi-automatic vessel edge detection 
algorithm with manual operator correction. The stroke volume was derived from 
the area under the flow curve and multiplied by heart rate (HR) to calculate 
cardiac output (CO). The maximum (AoMax) and minimum (AoMin) cross-
sectional areas of the ascending aorta over the cardiac cycle were also 
recorded.  
 
Local arterial stiffness was assessed by calculating ascending aortic compliance 
(AoC) = (AoMax – AoMin)/pulse pressure (65). Ascending aortic strain (AoS) 
was calculated as (AoMax – AoMin)/AoMin. 
 
Total systemic vascular resistance (SVR) was calculated by dividing MBP by 
CO (66). Total arterial compliance (TAC) was calculated using a two-element 
Windkessel model as described below (66).  
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The Windkessel effect refers to the buffering function of the aorta due to its 
elastic properties. It enables continuous peripheral blood flow despite the 
pulsatility of the heart. The two-element Windkessel model describes the 
exponential decay of pressure in diastole in relation to resistance and 
compliance. It is mathematically defined by the following equation:  
 
Q(t) = P(t)/R + C.dP(t)/dt 
 
Where Q(t) is the flow curve over time, P is pressure, C is total arterial 
compliance, and R is systemic vascular resistance.  
 
Briefly, aortic flow curves from the MR flow data and measured SVR were 
inputted into the model. Values of C between 0.1 and 5.0ml/mmHg in 
increments of 0.01 were inputted to obtain a series of modeled pressure curves 
(P). The pressure curves were used to calculate the modeled pulse pressure.  
The compliance was taken as the value that produced the best match with the 
non-invasive measured pulse pressure (Figure 4.5).  
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Figure 4.5: Figure showing calculation of compliance (Reproduced with 
permission from Steeden et al. (66)). Abbreviations: C=total arterial 
compliance, Q=flow, t=time, Q(t)=flow over time, P=pressure, 
R=resistance, and PP=pulse pressure. 
 
4.5 Statistics 
 
The statistical analyses were slightly different for each sub-study. They will be 
described in the respective chapters.  
 
4.6 Adapting the protocol for paediatric renal patients.  
 
There were unique challenges with the recruitment of paediatric renal patients 
that required protocol modifications and special provisions to be made. The 
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diagnosis of chronic kidney disease is associated with a high level of 
psychosocial burden for patients and their families. The main issues the patients 
and family faced as a result of their diagnosis were frequent hospital 
appointments resulting in missed school days, difficulties with arranging hospital 
visits around parental work schedule, impact of lost work days on family income 
and expensive transport costs. Furthermore, as the subjects were children, 
compliance with research protocol was more challenging than with an adult. 
 
All the CMR sequences used had been created for quick acquisition and were 
non-breathhold. Only one sequence (spiral SENSE PCMR for Aortic flow 
assessment) required a breath-hold. This breath-hold maneuver was practiced 
with the patient before the scan in order to minimise breathing artifacts and 
repeat acquisitions. In addition, sequence parameters were optimised for a 
child’s body size and to further reduce the acquisition time where possible. The 
total scan time was around 15 minutes. 
 
I undertook numerous measures to prevent and manage any potential anxiety 
the children might have felt about the scan. Child friendly leaflets were sent to 
the patients before the scan. On arrival for their appointment, I gave ample time 
to explain the procedure and answer any questions they may have. I also 
emphasised that they could stop the scan anytime if they felt afraid to continue, 
in order to give them a sense of being in control. Children who were 
apprehensive were shown round the scanner beforehand and had a ‘practice 
run’ of lying in the scanner. Parents were also encouraged to accompany the 
patient into the scan room during the scan to assuage their anxiety.  
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A DVD viewer facility was provided, which allowed them to watch a DVD while 
having the scan (Figure 4.6). This was one of the most effective measures in 
helping the patients tolerate the scan through distraction. Consequently, none of 
the children required sedation for the scan. 
 
 
 
Figure 4.6: DVD viewer facility consisting of mirror headset and TV behind 
the scanner. 
 
In order to make it as pleasant an experience as possible, the study protocol 
was designed to not include blood tests or require intravenous cannulation 
(Gadolinium administration was not required while blood tests results were 
obtained from their most recent clinic visit). Much effort was made to be as 
flexible and accommodating as possible when making logistical arrangements. 
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Appointments were scheduled to coincide with hospital appointments. When this 
was not possible, out of hours and weekend (including Sundays) appointments 
were offered. Reimbursements were also offered for transport costs to and from 
the hospital for the patient and any accompanying family members to cover any 
excess costs that they may have incurred as a result of the study.  
 
All of these measures together were helpful in ensuring that the scan was well 
tolerated by all patients who took part in the study. Based on the verbal 
feedback I received, their experience had been overwhelmingly positive, as the 
children felt empowered throughout the process. Many of the parents 
commented that participating in the research encouraged their children to better 
engage with their condition. Finally, the well-designed protocol and flexible 
logistic arrangements allowed the successful recruitment of large numbers of 
patients, which was important for the success of this study.   
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5 Comprehensive characterization of vascular 
phenotype in pre-dialysis chronic kidney disease  
 
In this chapter, I will describe the comprehensive evaluation of the vascular 
phenotype in children with CKD and determine its relationship with CKD 
severity. 
 
5.1 Personal contribution 
 
For the study described in this chapter:  
 I completed the ethics application process. 
 I recruited all subjects.  
 I acquired, collated, and tabulated the relevant clinical data.  
 I completed the segmentation and data analysis on all study subjects.   
 I performed statistical analysis on the study dataset. 
 I wrote up the findings from this study into a research article and have 
submitted it to Journal of Cardiovascular Magnetic Resonance. It is 
currently under review. 
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5.2 Introduction 
 
Children with chronic kidney disease have an excess of cardiovascular 
mortality (67), possibly due to associated arterial hypertension (12). In adult 
CKD, one of the main causes of HTN is thought to be increased arterial 
stiffness secondary to vessel wall calcification (68). These phenomena are 
also thought to play an important part in the development of HTN in children 
with CKD (14, 69-71). However, although several studies have demonstrated 
increased pulse wave velocity (72-74) in paediatric CKD, others have shown 
no difference compared to controls (75, 76) This conflicting evidence suggests 
that global arterial stiffness alone may not explain the increased prevalence of 
HTN in paediatric CKD (12). In fact, children with CKD also have other 
abnormalities that may predispose towards HTN (13). These include higher 
systemic vascular resistance, increased cardiac output and fluid overload 
(13). Unfortunately, few studies have investigated all these mechanisms 
together and this has made it difficult to determine their relative importance.  
 
Cardiovascular magnetic resonance is a reference standard method of 
assessing blood flow (77). It is routinely used in the paediatric population to 
assess cardiac output and valvar regurgitation. Importantly, CMR derived flow 
data can also be combined with simultaneous BP measurements to calculate 
SVR and total aortic compliance (78). Thus, CMR is the ideal method of 
comprehensively and non-invasively assessing the components of afterload in 
paediatric CKD.  
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The aim of this study was to use simultaneous CMR and blood pressure 
measurements to determine the vascular phenotype in pre-dialysis paediatric 
CKD. This was achieved by comparing pre-dialysis paediatric CKD patients 
with healthy (negative controls) and essential hypertensive (positive controls) 
subjects. 
 
5.3 Methods 
 
5.3.1 Study Population 
 
The study population consisted of 150 children: 110 with confirmed CKD, 20 
with primary essential hypertension (eHTN) and 20 healthy volunteers. All 
patients were recruited from the CKD and hypertension clinics at Great 
Ormond Street Hospital. Healthy subjects were recruited through hospital 
advertisements and a clinical history was taken to confirm there was no 
significant medical history or medications. Study exclusion criteria: i) age <7 
or >18 years, ii) congenital structural heart disease or primary myocardial 
disease, iii) active vasculitis iv) cardiac arrhythmia, v) secondary causes of 
hypertension (79), vi) medical devices that preclude CMR and vii) on-going 
renal replacement therapy or previous renal transplants, vii) patients with 
acute deterioration in renal function (only CKD patients with stable renal 
function were recruited).  
 
Results of standard clinical blood and urine tests performed as part of routine 
clinical care within 3 months of the study were collected in CKD patients. 
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These included; full blood count, urea, creatinine, electrolytes, serum calcium, 
phosphate, intact parathyroid hormone, and urine albumin to creatinine ratio 
measurements. The modified Schwartz formula was used to estimate 
glomerular filtration rate (eGFR) and CKD stage (eGFR = 36.2 x height in cm / 
serum creatinine in μmol/L). Blood and urine tests were not performed for the 
eHTN or healthy cohort, as this was not part of their on-going routine 
evaluation.  
 
5.3.2 Study protocol 
 
The study protocol has been previously outlined in detail in Chapter 4. In 
summary, I performed non-invasive blood pressure measurements, 
assessment of left ventricle (SAX LV stack acquisition using KT-SENSE 
sequence) and aortic flow (acquired in ascending aorta using retrospective-
gated, spiral SENSE PCMR sequence). This was used to calculate LV mass 
and volume and aortic flow and vascular characteristics as described below.   
 
Blood pressure measurements at the time of CMR were also used to divide 
the CKD patients into 2 groups. Children with SBP or DBP ≥95th percentile 
(61), or a previous clinical diagnosis of HTN irrespective of BP were 
considered to have hypertensive chronic kidney disease (H-CKD). All other 
children were considered to have normotensive chronic kidney disease (N-
CKD). 
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5.3.3 Statistics 
 
Statistical analyses were performed using Stata 13 (StataCorp, College 
Station, Texas, USA). Data were examined for normality using Shapiro-Wilk 
normality test and non-normally distributed data was transformed using a 
zero-skewness log transform to ensure normal distribution prior to analysis. 
Descriptive statistics were expressed as mean (± standard deviation) or 
geometric mean (± geometric standard deviation) if data was log transformed. 
To assess the effect of BP in CKD, comparisons were made between the H-
CKD, N-CKD, eHTN and healthy controls (HC). Between group differences 
were assessed using analysis of variance (ANOVA). Levene’s test was used 
to assess for homogeneity of variances across the groups and Welch’s 
correction was applied for non-homogeneous variance. To further interrogate 
differences between each group, a post-hoc pairwise comparison was 
performed on parameters significantly different on ANOVA testing. The 
Bonferroni method was employed to adjust for potential Type 1 errors in the 
post-hoc pairwise comparisons (build into post-hoc comparison method in 
Stata). Adjustments for sex, age and use of anti-hypertensive medication 
(including angiotensin converting enzyme (ACE) inhibitor, angiotensin-2 
receptor (AT2) inhibitor, calcium channel blocker (CCB) and or beta blockers 
(BB)) were made to examine for confounder effect where appropriate. Chi-
squared test was used to determine if sex distribution between groups were 
different. Pearson’s correlation (r coefficient) was used to assess the 
relationship between SBP and LVM or MVR. Spearman’s correlation (rho 
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coefficient) was used to interrogate the relationship between renal severity 
(eGFR and CKD stage) with BP and vascular indices. A p value < 0.05 was 
considered statistically significant. Indices not statistically different to healthy 
controls have been described as ‘normal’. 
 
5.4 Results 
 
5.4.1 Study Population 
 
The eHTN group was slightly older with higher BMI and a greater male 
preponderance, reflecting the typical demographics of these children (80) 
(Table 5.1). However, there were no demographic differences between the 
CKD and healthy control groups. Of the 110 CKD patients, the majority had 
congenital abnormalities of the kidney and urinary tract (n=65, 59%) or renal 
dysplasia (n=12, 10%). All other causes represented <10% of the population 
and are fully described in Table 5.2.  The distribution of CKD severity was: 
Stage 1 - 4 (4%), Stage 2 - 36 (33%), Stage 3 - 49 (45%), Stage 4 - 16 (14%), 
Stage 5 - 5 (4%). The mean eGFR in the CKD cohort was 54±24 ml/min/1.73 
m2. None of the children had previous renal transplantation or were on renal 
replacement therapy. Eight children had undergone a previous nephrectomy.  
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Table 5.1: Demographics and baseline characteristics of study population 
 HC 
N=20 
N-CKD 
N=67 
H-CKD 
N=43 
eHTN 
N=20 
p-value 
      
Age (years)* 11±1.3 11±1.3§ 12±1.3 14±1.2 0.01†† 
Sex (% male)§§ 60% 78% 53% 75% 0.05 
Height (cm) 158±19 149±20§ 151±17 164±13 0.003†† 
Weight (kg)* 48±1.4 42±1.5§ 44±1.4|| 66±1.4 <0.001 
BMI (kg/m2)* 20±1.1 19±1.2§ 19±1.2|| 25±1.3# 0 .002†† 
BSA (m2) 1.5±0.32 1.4±0.37§ 1.4±0.29|| 1.8±0.33 <0.001 
      
Recent blood test ‡‡      
Hemoglobin (g/L)  130±15 131±12  0.74 
Hematocrit (L/L)  0.38±0.042 0.38± 0.029  0.98† 
Mean Corpuscular Volume (fL)  82±4.7 81±3.8  0.19 
Platelet count (x109/L)*  250±1.3 263±1.3  0.44 
White Cell Count (x109/L)*  6.3±1.4 6.8±1.4  0.43 
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Sodium (mmol/L)  143±3 143±2.4  0.71 
Potassium (mmol/L)*  4±1.2 4.3±1.1  0.025 
Bicarbonate (mmol/L)  26±2.6 24±2.6  0.013 
Urea (mmol/L)*  9.6±1.6 8.2±1.7  0.26 
Creatinine (umol/L)*  134±1.7 125±2  0.65 
eGFR (ml/min/1.73 m2)  46±20 54±31  0.847† 
Magnesium (mmol/L)  0.85± 0.16 0.89± 0.1  0.20 
Chloride (mmol/L)  101±3.6 104±2.8  <0.001 
Alkaline phosphatase (U/L)  202±78 179±101  0.29 
Alanine transaminase (U/L)*  26±1.7 15±1.9  0.024 
Serum Albumin (g/L)*  43±1.1 42±1.2  0.48 
Calcium (mmol/L)*  2.4±1.1 2.4±1.1  0.61 
Phosphate (mmol/L)  1.4±0.17 1.5±0.24  0.045 
Calcium-Phosphate product (mmol2/L2)  3.3±0.43 3.5±0.51  0.068 
Ionised Calcium (mmol/L)  1.2±0.064 1.2±0.064  0.43 
Ionised Calcium pH corrected (mmol/L)  1.2±0.058 1.2±0.058  0.55 
Intact PTH (pmol/L)*  4.5±2.7 6.1±2.5  0.25 
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Recent urine test ‡‡      
Urine Albumin (mg/L)*  112±6.1 112±10  0.99 
Urine Creatinine  (mmol/L)*  4.9±2.3 4.5±2.3  0.76 
Urine Albumin/ Creatinine Ratio* (mg/mmol)  23±6.6 25±10  0.91 
      
Medications (%)      
ACE or AT2 Inhibitor   18% 47% 55% - 
Calcium Channel Blocker  0% 26% 50% - 
Beta-Blocker  0% 19% 15% - 
Aldosterone antagonist (Spironolactone)  1% 0% 5% - 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †- P-value <0.05 when N-CKD compared with HC. ‡ - P-value <0.05 when H-CKD compared with HC. §- P-value <0.05 
when N-CKD compared to eHTN. ||- P-value <0.05 when H-CKD compared to eHTN. #- P-value <0.05 when eHTN compared with HC.  **– P-value <0.05 when H-CKD compared to N-CKD. ††– ANOVA Welch 
(W) test was used. ‡‡ - Recent (within 3 months of CMR scan) blood test were only available in 68 CKD patients. §§-Chi-squared test was performed. Abbreviations: HC=Healthy control, N-CKD=Non hypertensive 
CKD, H-CKD=Hypertensive CKD, eHTN=Essential hypertension, BMI=Body mass index, BSA=Body surface area. eGFR=estimated glomerular filtration rate, PTH=Parathyroid hormone, ACE=angiotensin converting 
enzyme, AT2=angiotensin receptor 2.  
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Table 5.2: Proportion of CKD patients with other causes of primary renal 
disease. 
Type of Renal Disease N (% of total 
population) 
Renal cystic disease 6 (5%) 
Previous history of Haemolytic Uraemic syndrome 4 (4%) 
Previous history of acute tubular necrosis 4 (4%) 
Previous history of glomerulonephritis 3 (3%) 
Bartter syndrome  2 (2%) 
Chronic Tubule Interstitial Disease 2 (2%) 
Focal Segmental Glomerular Sclerosis 2 (2%) 
Cystinosis 2 (2%) 
Miscellaneous causes (comprised of hypercalciuric 
syndrome, nephrocalcinosis, Alport syndrome, previous 
Henoch Schonlein nephritis, renal ischaemic damage, 
cortical necrosis, Branchio-Oto-Renal syndrome and Lowe 
syndrome) 
8 (7%) 
 
All 26 CKD children with a previous diagnosis of hypertension were treated 
with anti-hypertensive medications (Table 5.1), apart from one whose 
medication was temporarily stopped while awaiting further investigations. A 
further 15 normotensive CKD children were treated with angiotensin 
converting enzyme inhibitors or angiotensin-2 receptor antagonists for 
proteinuria. A significant proportion of CKD patients were also receiving 
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additional treatments for CKD related complications (See Table 5.3 and Table 
5.4). Routine blood and urine tests, which had been performed within three 
months of the study, were available in 68 patients (Table 5.1). 
 
Table 5.3: Proportion of CKD patients with complications associated 
with CKD. 
Renal associated 
complications 
N (% of total 
population) 
Relevant Blood or Urine tests* 
Normocytic anemia 17 (15%) Hemoglobin: 112±10g/L 
Mean Corpuscular Volume: 81.9±3.8fL 
CKD Mineral Bone 
Disease 
40 (36%) Intact Parathyroid Hormone: 
11.9±8.4pmol/L 
Elevated Urine 
albumin/creatinine 
ratio (UACR) 
62 (56%) UACR: 140±261mg/mmol 
*- Blood and Urine test results presented as mean ± standard deviation. 
 
All eHTN patients had a diagnosis of primary hypertension and were receiving 
anti-hypertensive medication except for one child who was recruited before 
commencement of therapy. Six patients were on two or more anti-
hypertensive medications.  
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Table 5.4: Proportion of patients on treatment for complications 
associated with CKD 
 N (% of total population) 
Treatment for Anaemia  
Oral iron supplements 40 (36%) 
Erythropoietin (or analog) 16 (15%) 
Treatment for CKD Mineral Bone Disease  
Calcium supplements 42 (38%) 
Vitamin D supplements 75 (68%) 
Treatment for proteinuria  
ACE inhibitors 15 (14%) 
 
5.4.2 Blood pressure differences between groups  
 
Sixty-seven (61%) CKD patients were assigned to the N-CKD group. 
Nevertheless, MBP, DBP and DBP percentiles were still significantly higher 
(Table 5.5) in these children compared to healthy controls (p0.04).  
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Table 5.5: Comparison of blood pressure between groups. 
 HC 
N=20 
N-CKD 
N=67 
H-CKD 
N=43 
eHTN 
N=20 
p-value 
SBP (mmhg) 105±11 108±8.6 124±12‡** 127±12#§ <0.001 
DBP (mmhg) 53±6.8 60±6.8† 72±11‡** 65±12#|| <0.001†† 
MBP (mmhg) 75±7 81±5.7† 93±9.5‡** 90±10#§ <0.001†† 
PP (mmhg) 52±12 48±9.6 51±11 62±8.7#§|| <0.001 
SBP percentile* 31±2.1 47±1.9 80±1.6‡** 78±1.4#§ <0.001†† 
DBP percentile* 18±2.2 37±1.9† 68±1.5‡** 36±2.4#|| <0.001†† 
Heart Rate (BPM)* 74±1.2 74±1.2 75±1.2 80±1.2 0.45 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †- P-value <0.05 when N-CKD compared with HC. ‡ - P-value <0.05 when H-
CKD compared with HC §- P-value <0.05 when N-CKD compared to eHTN. ||- P-value <0.05 when H-CKD compared to eHTN. #- P-value <0.05 when eHTN compared 
with HC.  **– P-value <0.05 when H-CKD compared to N-CKD. ††– ANOVA Welch (W) test was used. Abbreviations: HC=Healthy control, N-CKD=Non hypertensive 
CKD, H-CKD=Hypertensive CKD, eHTN=Essential hypertension, SBP=Systolic blood pressure, DBP=Diastolic blood pressure, MBP=Mean blood pressure, PP=Pulse 
pressure. 
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Forty-three (39%) CKD patients were assigned to the H-CKD group. Of these, 
26 had a previous diagnosis of HTN (12 controlled and 14 uncontrolled) and 
17 were hypertensive during the CMR exam. Absolute SBP, MBP and DBP, 
as well as BP percentiles (Table 5.5), were significantly higher in H-CKD 
compared to both healthy controls and N-CKD patients (p<0.001). There were 
no significant differences in PP between healthy controls, and either CKD 
sub-groups.  
 
In eHTN patients, SBP, SBP percentile and MBP were elevated compared to 
the healthy controls and N-CKD patients (p<0.001) and similar (p=1.0) to H-
CKD patients (Table 5.5). The DBP and DBP percentile were higher 
compared to healthy subjects (p<0.001), similar to N-CKD (p≥0.30) and lower 
than in H-CKD (p0.01). Pulse pressure was also significantly elevated 
(p0.02) in eHTN patients compared to healthy controls and both CKD 
groups.  
 
The between group differences remained after adjustment for age, sex and 
anti-HTN medication use. 
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5.4.3 Components of blood pressure between the groups 
 
There was no significant difference in TAC between healthy controls and 
either of the CKD sub-groups (p>0.50 - Table 5.6). However, the eHTN group 
had significantly lower TAC compared to healthy controls and both CKD sub-
groups (p<0.04), as seen in Figure 5.1. The between groups differences 
remained after adjustment for age, sex and anti-HTN medication use. 
Although AoC was lower in eHTN compared to N-CKD (p=0.011), this was no 
longer significant after correction for age, sex and anti-HTN medication use. 
There were no other significant differences in AOC between the groups.  
 
Compared to healthy controls (Table 5.6), SVR was significantly higher in the 
H-CKD group (p<0.001), and trended towards higher in the N-CKD group 
(p=0.06), as can be seen in Figure 5.2. In addition, SVR was higher in the H-
CKD patients compared to N-CKD patients (p=0.03). There was a trend 
towards greater SVR in the eHTN patients compared to controls (p=0.10), but 
there were no differences compared to the CKD sub-groups. Between group 
differences remained after adjustment for age, sex and anti-HTN medication 
use. 
 
There were no significant differences (Table 5.6) in RA size, IVC size or CO 
between the three groups with and without adjustment for age, sex and anti-
HTN medication use.  
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Table 5.6: Determinants of blood pressure and indices of ascending aortic stiffness between groups. 
 HC 
N=20 
N-CKD 
N=67 
H-CKD 
N=43 
eHTN 
N=20 
p-value 
SVR (WU.m2)* 20±1.2 23±1.2 26±1.2‡** 24±1.2 <0.001 
TAC (ml/mmHg. m2)* 0.54±1.3 0.58±0.3 0.54± 1.2 0.45±1.2#§|| <0.001 
CO (l/min/m2)* 3.7±1.2 3.5±1.2 3.6±1.2 3.8±1.2 0.26 
RAA (cm2/m2) 12±1.8 11±2 12±2.3 11±1.4 0.16 
IVCA (cm2/m2)* 2.4±1.2 2.3±1.3 2.3±1.2 2.1±1.4 0.51 
AoS (%)*   47±1.6   54±1.6   52±1.6   51±1.7  0.73 
AoC (cm2.mmHg-1.10-2)* 2.8±1.6 3.1±1.5§ 2.9±1.4 2.2± 1.5 0.02 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †- P-value <0.05 when N-CKD compared with HC. ‡- P-value <0.05 when 
H-CKD compared with HC §- P-value <0.05 when N-CKD compared to eHTN. ||- P-value <0.05 when H-CKD compared to eHTN. #- P-value <0.05 when eHTN 
compared with HC.  **– P-value <0.05 when H-CKD compared to N-CKD. ††– ANOVA Welch (W) test was used. Abbreviations: HC=Healthy control, N-CKD=Non 
hypertensive CKD, H-CKD=Hypertensive CKD, eHTN=Essential hypertension, SVR=Systemic vascular resistance, TAC=Total arterial compliance, CO=Cardiac 
output, RAA=Right atrial area, IVCA=Inferior vena cava area, AoS=Ascending aortic strain, AoC=Ascending aortic compliance. 
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Figure 5.1: Bar chart showing differences in TAC between groups: TAC 
is significantly (p<0.05) lower in eHTN compared to all the other groups. 
Abbreviations: TAC=total arterial compliance, N-CKD=non-hypertensive 
chronic kidney disease group, H-CKD=hypertensive chronic kidney 
disease group, eHTN=essential hypertension group. 
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Figure 5.2: Bar chart showing differences in SVR between groups:  SVR 
is significantly (p<0.05) higher in H-CKD compared to healthy controls 
and N-CKD. Abbreviations: SVR=systemic vascular resistance, N-
CKD=non-hypertensive chronic kidney disease group, H-
CKD=hypertensive chronic kidney disease group, eHTN=essential 
hypertension group. 
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5.4.4 Assessment of Left Ventricular indices 
 
Systolic blood pressure was significantly correlated with LVM (r=0.40, 
p<0.0001) and MVR (r=0.40, p<0.0001) when the population was considered 
as a whole.  
 
There was no difference in LVMht2.7 between the CKD groups compared to 
healthy children but was higher in eHTN (Table 5.7). Conversely, MVR was 
significantly different between the groups (p=0.004). Both H-CKD and eHTN 
trended towards a higher MVR when compared to controls (p=0.054 and 
0.061, respectively).  
 
5.4.5 Relationship between Blood Pressure, Vascular Indices and Renal 
Severity  
 
In CKD patients, higher MBP and DBP were significantly associated with 
lower eGFR and higher CKD stage (Table 5.8). For SBP, these associations 
were only a trend (p = 0.055 and 0.083 respectively). There was also a trend 
between higher SVR and CKD stage, but not with eGFR (Table 5.8). There 
were no associations between TAC and either CKD stage or eGFR. There 
were no associations between blood and urine based biomarkers of 
complications associated with CKD (calcium phosphate product, parathyroid 
hormone level, and urine albumin to creatinine ratio) with BP, SVR and TAC. 
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Table 5.7: Conventional indices of left ventricular assessment. 
 HC 
N=20 
N-CKD 
N=67 
H-CKD 
N=43 
eHTN 
N=20 
p-value 
LVEDV (ml/m2) 72±10 67±9.5 67±10 69±9.6 0.20 
LVESV (ml/m2)* 23±1.3 20±1.3 19±1.3 21±1.3 0.21 
LVSV (ml/m2) 50±6.5 47±6.1 48±8.2 48±6.6 0.56 
EF (%) 68±4.5 69±5.8 70±6.7 69±4.2 0.78†† 
LVMht2.7 (g/m2.7)   21±3.6   22±4.9§   24±5.9   26±6.5# 0.008 
MVR (g/ml) 0.68±0.095 0.72±0.16 0.79±0.18 0.81±0.14 0.004†† 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †- P-value <0.05 when N-CKD compared with HC. ‡ - P-value <0.05 when 
H-CKD compared with HC §- P-value <0.05 when N-CKD compared to eHTN. ||- P-value <0.05 when H-CKD compared to eHTN. #- P-value <0.05 when eHTN 
compared with HC.  **– P-value <0.05 when H-CKD compared to N-CKD. ††– ANOVA Welch (W) test was used. Abbreviations: HC=Healthy control, N-CKD=Non 
hypertensive CKD, H-CKD=Hypertensive CKD, eHTN=Essential hypertension, LVEDV=Left ventricular end-diastolic volume, LVESV=Left ventricular end-systolic 
volume, LVSV=Left ventricular stroke volume, EF=Ejection fraction, LVMht(2.7)= Left ventricular mass indexed to height to the power of 2.7, MVR= Left ventricular 
mass volume ratio. 
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Table 5.8: Relationship between blood pressure, vascular indices and renal severity. 
 CKD cohort with recent bloods, N=68 
 eGFR* 
Rho 
p-
value 
CKD Stage* 
Rho 
p-value 
SBP (mmhg) -0.23 0.055 0.21 0.083 
MBP (mmhg) -0.29 0.015 0.31 0.011 
DBP (mmhg) -0.27 0.028 0.29 0.015 
SVR (WU.m2) -0.15 0.23 0.21 0.093 
TAC (ml/mmHg. m2) -0.01 0.92 0.04 0.77 
Data presented as mean ± standard deviation. *-Spearman’s correlation was applied. Abbreviations: CKD=Chronic kidney disease, eGFR=Estimated glomerular filtration 
rate, Rho=Spearman Correlation Coefficient, SBP=Systolic blood pressure, DBP=Diastolic blood pressure, MBP=Mean blood pressure, SVR=Systemic vascular 
resistance, TAC=Total arterial compliance. 
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5.5 Discussion 
 
In this study, I used CMR to investigate vascular phenotype in paediatric 
CKD. The main finding was that SVR was significantly elevated in 
hypertensive and non-hypertensive CKD patients, but TAC was normal.  
 
5.5.1 Hypertension in CKD 
 
I have shown that the vascular phenotype of paediatric CKD is different from 
both healthy children (negative controls) and eHTN patients (positive 
controls). In eHTN, there were signs of arterial stiffening (reduced TAC) and 
BP characteristics consistent with stiffening being the cause of HTN 
(predominantly raised SBP and PP). In contrast, compliance was normal in 
CKD and the changes in BP (high SBP, DBP and MBP with normal PP) were 
in keeping with the raised SVR. This goes against the assumption that 
increased arterial stiffness is the main cause of hypertension in paediatric 
CKD (81).  
 
The role of arterial stiffness in the aetiology of paediatric CKD related HTN 
has been inferred from 2 important findings. The first is the demonstration of 
raised pulse wave velocity (PWV), as recently shown in the 4C’s study (74). 
However, raised PWV is not a universal finding and even in positive studies, 
PWV is only mildly raised (i.e. in the 4C’s study the PWV z-score was 0.33 
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(74)). Furthermore, pulse pressure is normal in larger paediatric CKD studies 
(75), suggesting that global arterial stiffness is not increased in the population. 
The second finding is the observation of arterial wall calcification in children 
with CKD. Calcification does increase wall stiffness (82). However, it appears 
limited to muscular arteries (14, 69-71, 83) (e.g. the mesenteric and carotid 
arteries). There may be aortic sparing in pre-dialysis children due to the 
limited expression of vascular smooth muscle cells (implicated in calcification) 
in the media (83, 84). The aorta is the main repository of arterial compliance 
(85) (~80%). Therefore, it is possible to have stiff muscular arteries with 
normal total arterial compliance. Thus, my results are not inconsistent with the 
published data in pre-dialysis children.  
 
The main difference between CKD patients and healthy controls was 
significantly higher SVR. In addition, SVR was higher in H-CKD patients 
compared to N-CKD patients and trended towards being higher with 
increasing CKD stage. This mirrors the BP associations seen in these 
patients, which was not the case for total arterial compliance. These findings 
suggest that SVR does play a role in the development of HTN, although my 
data does not prove causation. There are several possible explanations for 
increased SVR in CKD. They include salt retention and abnormal renin-
angiotensin stimulation (86), and sympathetic overdrive (87).  
 
Renin-angiotensin-aldosterone system (RAAS) activation is the hallmark of 
renal disease. Renal impairment begins with nephron injury and loss of 
glomeruli, which can be triggered by any pathological process. This causes 
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hyperfiltration and glomerular capillary hypertension, resulting in progressive 
glomerular injury and pressure induced capillary stretch. This leads to 
subsequent activation of intra-renal RAAS. The increased local production of 
angiotensin 2 creates a vicious cycle of glomerular damage by exacerbating 
efferent arteriolar vasoconstriction. It also promotes proteinuria and renal 
fibrosis, which in turn result in further renal injury and RAAS activation. 
Increased RAAS activity is associated with systemic vasoconstriction (88). 
 
Sympathetic overactivity is another feature of CKD. Renal injury or ischaemia 
is thought to trigger several potential mechanisms including impaired reflex 
control of autonomic activity, stimulation of renin-angiotensin-aldosterone 
system and activation of renal afferent signals. The resultant increase in 
sympathetic activity promotes vasoconstriction, accelerated atherosclerosis 
and left ventricular hypertrophy (89).  
 
Salt retention is a direct consequence of CKD and worsens with renal 
dysfunction (90). In renal failure, the salt and water accumulation leads to 
increase circulating blood volume. In healthy individuals, fluid retention 
secondary to increased oral salt intake (mediated via vasopressin), causes 
small increases in intraglomerular pressure that result in higher clearance of 
sodium. This is a normal mechanism for salt clearance and is known as 
pressure natriuresis. In CKD, this process is dysfunctional (86), which further 
exacerbates sodium retention. Furthermore, sodium causes an increase in 
SVR through direct effects on the vascular endothelium (causing peripheral 
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vasoconstriction) and indirect effects mediated via other mechanisms such as 
altered sympathetic activity (91).  
 
Determination of the exact mechanism by which SVR is elevated in paediatric 
CKD was not the main purpose of this study, but would be an important next 
step. 
 
Other possible causes of hypertension in CKD are fluid overload or high 
cardiac output. Although fluid overload is difficult to assess, I did show that 
RAA (a marker of fluid overload) was normal in this cohort. Furthermore, I 
also demonstrated that CO was not increased in CKD. Therefore, it is unlikely 
that these factors are important in the pathogenesis of HTN in early CKD.  
 
In this study, I also showed a trend towards LV hypertrophy in eHTN and H-
CKD patients when assessed using LV mass volume ratio. However, there 
was no statistically significant difference in indexed LV mass between the 
CKD and healthy control groups. Nevertheless, there was still a strong 
association between BP and both LVM and MVR. 
 
5.5.2 Vascular phenotyping methodology 
 
Most studies in paediatric CKD use PWV measurements to determine 
vascular phenotype, specifically arterial stiffness. However, PWV does not 
directly reflect the total buffering capacity of the arterial bed and can be 
difficult to assess accurately in children. Furthermore, PWV does not provide 
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any information about SVR, which is the main component of afterload. 
Therefore, in this study, I simultaneously assessed flow and BP to calculate 
both SVR and TAC, which allows more robust determination of vascular 
phenotype. Importantly, phase contrast MR provides more accurate 
assessment of flow compared to other techniques such as impedance 
cardiography or echocardiography. Nevertheless, there are some important 
points that should be addressed regarding this technique. Firstly, it is possible 
that TAC is a poor measure of stiffness and my findings in CKD are falsely 
negative. To guard against this, I included eHTN patients as positive controls 
and as expected (92) these children did have reduced TAC. Thus, I believe 
this method is valid and sufficiently sensitive for evaluating global arterial 
stiffness. Secondly, I did not include RA pressure in my calculation of SVR 
and if raised this could cause SVR to appear falsely elevated. However, the 
RA pressure would have to be extremely high (almost 20mmHg greater than 
normal in H-CKD patients) to explain these results. The fact that RA size was 
normal and there were no other signs of severe fluid overload suggests that 
this method of measuring SVR is valid in these children.  
 
5.6 Limitations 
 
The main limitation of this study was the fact that the eHTN population were 
older and had a male preponderance. This problem was overcome for SBP 
and DBP by using blood pressure percentiles for age and gender. However, 
percentiles are not readily available for other parameters such as SVR and 
TAC and BSA indexing may not be sufficient.  
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Another limitation of the study comes from the fact that most CKD patients 
were already on antihypertensive medications at the time of the study and this 
may have biased the results. Because of this, adjustments for the potential 
confounding effect of sex, age and use of anti-HTN medications were 
additionally undertaken to interrogate the influence of these factors. The exact 
pubertal status of patients was not assessed and this is a limitation as 
pubertal status can affect hemodynamic parameters. The control group were 
relatively small in sample size. However, the numbers were sufficiently 
powered to detect the differences. 
 
Blood pressure measurements were carried out using an oscillometric 
sphygmomanometer, which may be less accurate than using manual 
sphygmomanometer (93). This was because it was essential for BP 
measurement to be acquired simultaneously during PCMR flow acquisition for 
accurate assessment of vascular measures. Unfortunately, this could not be 
performed manually in the CMR scanner during flows acquisitions. However, 
BP measurement was taken with a standardized protocol for all subjects using 
the same machine. This meant that the measurements were comparable 
across the cohort. Therefore, I believe that the group wise differences noted 
are a reflection of real differences.  
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Finally, calculation of compliance using central aortic PP, instead of brachial 
PP, may provide a more accurate assessment of arterial stiffness. This is 
because brachial PP is believed to be a surrogate of central aortic PP due to 
the amplification phenomenon (65). There are methods to estimate central 
aortic PP from brachial PP such as the reconstruction of central aortic 
pressure waveforms by applying a Generalised Transfer Factor to the 
peripheral blood pressure waveform (94). However, as these methods may 
not be accurate, the direct measurement of central PP for arterial stiffness 
assessment would be ideal. Unfortunately, this is challenging to perform non-
invasively during a CMR scan and was not done.  Despite that, I was able to 
demonstrate a significant difference between groups in compliance calculated 
using brachial PP. Future studies should consider assessing central aortic 
pressure in these patient groups to determine if it differs with my findings.  
 
5.7 Conclusion  
 
In this study, I have shown that systemic vascular resistance, not aortic 
stiffness, is increased in paediatric CKD. My data suggests elevated BP in 
CKD is associated with increased resistance rather than reduced compliance. 
This novel finding may be important in determining the optimum 
antihypertensive therapy for these children. Hopefully, improved directed 
treatment will reduce cardiovascular risk in paediatric CKD. 
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6 Comprehensive characterization of cardiac 
phenotype in pre-dialysis chronic kidney disease  
 
In this chapter, I will describe the comprehensive evaluation of the cardiac 
phenotype in children with CKD and determine its relationship with CKD 
severity. 
 
6.1 Personal contribution 
 
For the study described in this chapter:  
 I completed the ethics application process. 
 I recruited all subjects.  
 I acquired, collated, and tabulated the relevant clinical data.  
 I completed the segmentation and data analysis on all study subjects.   
 I performed statistical analysis on the study dataset. 
 I wrote up the findings from this study into a research article and have 
submitted it to Journal of Cardiovascular Magnetic Resonance. It is 
currently under review. 
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6.2 Introduction 
 
Cardiovascular events are a leading cause of death in paediatric chronic 
kidney disease (95). Unfortunately, reducing mortality in this group remains 
challenging, partly due to difficulties in identifying children at risk.   
 
Two-dimensional echocardiography is conventionally used to assess the heart 
in children with CKD. Several ECHO markers have been used as indicators of 
increased risk including left ventricle hypertrophy and left ventricular global 
dysfunction (i.e. reduced ejection fraction) (96, 97). More recently, there has 
been increasing interest in advanced ECHO techniques like tissue Doppler 
and speckle tracking, which have demonstrated sub-clinically impaired 
diastolic and systolic function in paediatric CKD. However, the utility of ECHO 
is significantly limited by inaccurate measurement of volumes and mass, 
limited reproducibility and operator dependence (22). 
 
Cardiovascular magnetic resonance imaging is the reference standard 
method of assessing LV volumes, ejection fraction and mass (77). Robust 
evaluation of the left ventricle by CMR is vital as the LV represents a possible 
pathophysiological link between increased mortality and co-morbidities such 
as hypertension. Of particular note is LV mass, which is an independent risk 
factor for sudden cardiac death in adult CKD (98).   
 
New CMR techniques are also being developed that could provide more 
sophisticated evaluation of cardiac function. These include tissue phase 
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mapping to assess myocardial velocities (59) and high temporal resolution 
phase contrast MR to measure mitral inflow velocities and cardiac timing 
intervals, as previously discussed in Chapter 2. Thus, CMR may be a useful 
technique to comprehensively assess myocardial phenotype in paediatric 
CKD.  
 
The objectives of this study were to i) perform comprehensive cardiac 
phenotyping of children with CKD, and ii) determine the relationship between 
phenotype and CKD severity. To accomplish this, CMR was performed in a 
large cohort of pre-dialysis CKD children and findings were compared with 
healthy subjects. 
 
6.3 Methods 
 
6.3.1 Study Population 
 
The study population consisted of 120 children: 100 with confirmed CKD 
(stages 1-5) and 20 healthy volunteers. Exclusion criteria were: i) age <7 or 
>18 years, ii) congenital structural heart disease or primary myocardial 
disease, iii) primary renovascular disease, iv) active vasculitis v) cardiac 
arrhythmia, vi) medical devices precluding CMR, vii) history of current or 
previous renal replacement therapy and viii) acutely deteriorating renal 
function.  
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The data presented in this chapter was collected together (at the same sitting) 
as the vascular data presented in Chapter 5. Ten children from the original 
pre-dialysis CKD cohort (n=110) had the vascular assessment protocol but 
did not manage to complete the myocardial assessment protocol for logistic 
reasons (e.g. needed to leave the hospital early due to time pressures) and 
were excluded from this analysis.  
 
All CKD participants had blood and urine tests as part of their outpatient care 
including: haemoglobin (HB), urea, creatinine, electrolytes, calcium, 
phosphate, intact parathyroid hormone level (PTH), and urine albumin to 
creatinine ratio measurements. Estimated glomerular filtration rate was 
estimated by modified Schwartz formula. All medical notes were also 
reviewed specifically looking for previous renal function to confirm that the 
documented renal function results is stable and there is no clinical suspicion 
of renal deterioration. Neither blood nor urine tests were performed for healthy 
controls.  
 
6.3.2 Study protocol 
 
The study protocol has been previously outlined in detail in Chapter 4. In 
summary, I performed non-invasive blood pressure measurements, and 
assessment of left ventricle (SAX LV stack acquisition using KT-SENSE 
sequence), aortic flow (acquired in ascending aorta using retrospective-gated, 
spiral SENSE PCMR sequence), cardiac timing (acquired at the LV 
inflow/outflow SAX position using real-time UNFOLD-SENSE spiral PCMR 
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sequence) and myocardial velocity (acquired in Mid LV SAX position using 
self-navigated golden-angle spiral TPM sequence). This was used to calculate 
LV mass and volume, aortic flow, cardiac timing and myocardial velocity 
measures as described below.   
 
6.3.3 Statistics 
 
Statistical analyses were performed using Stata 13 (StataCorp, College 
Station, Texas, USA). Data were examined for normality using Shapiro-Wilk 
test and non-normally distributed data was transformed using a zero-
skewness log transform prior to analysis. Descriptive statistics were 
expressed as mean (± standard deviation) or geometric mean (± geometric 
standard deviation) if data was log transformed.  
 
To assess the CKD group, the patients were divided into 3 CKD groups – 
stages 1–2, stage 3a–3b and stage 4–5 and compared to healthy controls. 
Between group differences were assessed using analysis of variance 
(ANOVA). The ANOVA models were adjusted for confounders like age, sex, 
where indicated.  Levene’s test was used to assess for homogeneity of 
variances across the groups and Welch’s correction was applied for non-
homogeneous variance. To further interrogate differences between each 
group, a post-hoc pairwise comparison was performed on CV parameters 
significantly different on ANOVA testing. The Bonferroni method was 
employed to adjust for potential Type 1 errors in the post-hoc pairwise 
comparisons (build into post-hoc comparison method in Stata).  
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Spearman’s correlation coefficient (rho) was used to determine the 
relationship between continuous variables as further described in the results 
section. Chi-square test was used to determine differences in sex distribution 
and the proportion of anti-hypertension medication use between the groups. 
 
Separate multi-variable ANOVA models were also constructed to examine the 
independent effect of CKD group and other significant correlates on various 
CV characteristics, namely: i) the effect of CKD and SBP on LV remodeling, ii) 
effect of CKD and MVR on IRT, and iii) effect of CKD and DBP on radial S’ 
velocity. All models were adjusted for the influence of age and sex.  
 
Finally, multi-variable linear regression was also used to determine if 
significant CV indices (MVR, IRT, S’, E’, E’/A’, E/E’) were related to eGFR or 
other markers of CKD severity i.e. anaemia (HB) and CKD-mineral bone 
disease (PTH). Adjusted R2 was used to assess for goodness of fit. The beta 
coefficient (β) was used to evaluate the relationship between the dependent 
variable and the independent factors in the regression model. Only patients 
with recent blood tests (within 3 months of CMR scan) were included into 
models involving blood indices. A p value <0.05 was considered statistically 
significant. Indices not statistically different to healthy subjects have been 
described as ‘normal’. 
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6.4 Results 
 
6.4.1 Demographics 
 
The CKD cohort (n=100) consisted of 40 children in stage 1-2 (group 1: mean 
eGFR: 78.6±8.8 ml/min/1.73 m2), 40 children in stage 3 (group 2: 48.3±8.4 
ml/min/1.73 m2) and 20 children in stage 4-5 (group 3: 19.2±6.5 ml/min/1.73 
m2). Twenty-five (25%) children (group 1: 10, group 2: 9 and group 3: 6) had a 
prior diagnosis of HTN and were on treatment (Table 6.1). The two most 
common causes of CKD were congenital abnormalities of the kidney and 
urinary tract (CAKUT, n=60, 60%) and renal dysplasia (n=11, 11%). All other 
causes represented <10% of the population. Eight CKD children had 
undergone a previous nephrectomy. No children had previously received or 
were currently receiving renal replacement therapy as per exclusion criteria. 
None of the healthy subjects (n=20) had any significant past medical history 
nor were taking any medications. There were no differences in age, BSA or 
sex distribution between groups (Table 6.1). Recent blood and urine test were 
available in 62 patients (group1: n=16, group 2: n=28, group 3: n=18) and are 
summarised in Table 6.1. 
 
Both DBP and MBP were significantly elevated in CKD as seen in Table 6.1. 
In addition, DBP centile was higher in CKD (p<0.001). There were no group 
differences in SBP and PP (p≥0.13), although there was a trend towards a 
higher SBP centile in CKD (p=0.08).  
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Table 6.1: Demographics and baseline characteristics of study population. 
 Healthy Controls 
(n=20) 
Group 1 CKD 
(n=40) 
Group 2 CKD 
(n=40) 
Group 3 CKD 
(n=20) 
p-value 
Age (years)* 12±1.3 11±1.3 12±1.3 13±1.3 0.12 
Sex (% male) 40% 38% 23% 45% 0.42 
Height (cm) 162±18 150±17 152±18 151±18 0.075 
Weight (kg)* 53±1.4 43±1.5 45±1.5 44±1.4 0.22 
Body Mass Index (kg/m2)* 20±1.1 19±1.2 20±1.2 20±1.1 0.77 
Body Surface Area (m2) 1.6±0.32 1.4±0 .33 1.4±0.35 1.4±0.3 0.16 
Systolic BP (mmhg)* 109±1.1 113±1.1 116±1.1 116±1.1 0.14 
SBP percentile* 33±2.5 58±1.7 61±1.8 64±1.7 0.08†† 
Diastolic BP (mmhg)* 53±1.2 63±1.2† 65±1.2‡ 69±1.2§ <0.001 
DBP percentile* 17±2.3 45±1.9† 48±1.8‡ 60±1.6§ <0.001†† 
Mean BP (mmhg) 78±7.8 84±8.8† 87±9.9‡ 89±8.8§ <0.001 
Pulse Pressure (mmhg) 55±13 50±10 51±9.5 48± 12 0.13 
Heart Rate (BPM)* 72±1.2 75±1.2 72±1.2 74±1.2 0.75 
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Relevant blood results‡‡      
Haemoglobin (g/L) - 132±13 133±16 128±11 0.57 
Urea (mmol/L) - 5.4±1.2 8.6±2.5|| 18.0±5.2#** <0.001†† 
Creatinine (umol/L)* - 68±1.2 117±1.2|| 305±1.4#** <0.001†† 
eGFR (ml/min/1.73 m2) - 79±8.8 48±8.4|| 19±6.5#** <0.001 
Calcium-Phosphate product (mmol2/L2) - 3.4±0.45 3.4±0.39 3.5±0.56 0.40 
Intact parathyroid hormone (pmol/L)* - 3.5±3.2 3.7±2.4 8.5±2.4** 0.011 
Urine Albumin/ Creatinine Ratio (mg/mmol) - 4.7±3.7 22±6.2 261±2.5#** <0.001 
Medications§§      
Angiotensin converting enzyme inhibitor - 28% 40% 15% 0.13 
Calcium Channel Blocker - 5% 13% 15% 0.38 
Beta-Blocker - 5% 5% 20% 0.09 
Aldosterone antagonist (Spironolactone) - 3% 0% 0% 0.47 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †- P-value <0.05 when group 1 compared with controls. ‡ - P-value <0.05 when group 2 compared with controls. §- P-value 
<0.05 when group 3 compared with controls. ||- P-value <0.05 when group 2 compared with group 1. #- P-value <0.05 when group 3 compared with group 1.  **– P-value <0.05 when group 3 compared with group 2. 
††– ANOVA Welch (W) test was used. ‡‡ - Recent (within 3 months of CMR scan) blood test were available in 62 CKD patients. §§-Chi-squared test was performed. 10% of CKD patients were on 2 or more anti-
hypertensive agents. Abbreviations: CKD= chronic kidney disease, eGFR=Estimated glomerular filtration rate. 
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6.4.2 Cardiac geometry and global function 
 
Mass volume ratio (a marker of LV remodeling) was elevated in CKD, with the 
highest MVR observed in group 3 (Table 6.2). This finding remained 
significant after adjusting for age and sex (p=0.009). Mass volume ratio 
correlated with all measures of blood pressure (SBP: rho=0.29, p=0.001; 
MBP: rho=0.26, p=0.004; and DBP: rho=0.19, p=0.04) as seen in Figure 6.1. 
When a model was created to study the combined effect of blood pressure 
and renal disease severity on LV remodeling, both SBP (BP with highest 
univariate correlation) and CKD group were independent predictors of MVR 
(p=0.003, p=0.02 respectively).  
 
Although LVMht2.7 did appear higher in CKD, this did not reach statistical 
significance (p=0.12).  
 
There were no differences in ESV, SV, EF, RAA or LAA between the groups. 
However, LV EDV was slightly smaller in CKD groups compared to controls 
(p=0.03). 
 
 
 
 112 
Table 6.2: Cardiac structure and global function in CKD. 
 Healthy Controls 
(n=20) 
Group 1 CKD 
(n=40) 
Group 2 CKD 
(n=40) 
Group 3 CKD 
(n=20) 
p-value 
LVEDV (ml/m2) 74±11 68±9.1† 68±10 65±9.7§ 0.03 
LVESV (ml/m2)* 23±1.3 21±1.3 20±1.3 19±1.3 0.13 
LVSV (ml/m2)* 50±1.1 46±1.1 47±1.2 46±1.2 0.18 
CO* (l/min/m2) 3.6±1.2 3.5±1.2 3.4±1.2 3.4±1.2 0.61 
EF (%) 68±4.6 68±6.1 69±6.7 70±5.8 0.72 
LVMht2.7 (g/m2.7)* 21±1.2 21±1.3 22±1.2 25±1.2 0.12 
MVR (g/ml) 0.7±0.1 0.72±0.16 0.75±0.16 0.87±0.17§#** 0.003 
RAA (cm2/m2) 12±1.8 12±1.9 11±2.5 11±2 0.69 
LAA (cm2/m2)* 12±1.3 12±1.2 11±1.2 11±1.2 0.38 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †- P-value <0.05 when group 1 compared with controls. ‡ - P-value <0.05 when group 2 compared with controls. §- P-
value <0.05 when group 3 compared with controls. ||- P-value <0.05 when group 2 compared with group 1. #- P-value <0.05 when group 3 compared with group 1.  **– P-value <0.05 when group 3 compared with 
group 2. ††– ANOVA Welch (W) test was used.  Abbreviations: CKD=Chronic kidney disease, LVEDV=Left ventricular end-diastolic volume, LVESV=Left ventricular end-systolic volume, LVSV=Left ventricular 
stroke volume, LVMht(2.7)=Left ventricular mass indexed to height to the power of 2.7, MVR=Left ventricular mass to volume ratio, R/LAA =Right / left atrial area, EF=Ejection fraction, CO =Cardiac output. 
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Figure 6.1: Relationship between mass volume ratio (MVR) and 
cardiovascular characteristics: (a) MVR versus systolic blood pressure 
(SBP), (b) MVR versus isovolumic relaxation time (IRT). The 95% 
confidence interval of the predicted mean is illustrated by grey zone. 
 
6.4.3 Inflow velocities and cardiac timing intervals 
 
Isovolumic relaxation time (a marker of active myocardial relaxation (99)) was 
prolonged in CKD and significantly increased in CKD groups 2 and 3 (Table 
6.3). This remained significant after adjustments for age and sex and heart 
rate. There was a significant association between IRT and MVR (rho=0.25, 
p=0.008) as seen in Figure 6.1.  
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Table 6.3: Cardiac timings and mitral inflow velocities in CKD 
 Healthy Controls 
(n=20) 
Group 1 CKD 
(n=40) 
Group 2 CKD 
(n=40) 
Group 3 CKD 
(n=20) 
p-value 
IRT (ms)* 61±1.2 64±1.1 70±1.1‡ 72±1.1§ <0.001 
ICT (ms)* 44±1.6 36±1.6 33±1.8 37±1.8 0.24 
ET (ms) 277±21 275±16 274±19 276±15 0.92 
Tei* 0.39±1.3 0.37±1.2 0.38±1.2 0.41±1.3 0.56 
E (mls) 47±9.8 49±11 50±11 49±9.7 0.87 
A (mls) 19±4.3 20±6.7 21±6.8 22±5.6 0.36 
E/A ratio* 2.6±1.2 2.6±1.4 2.5±1.5 2.3±1.3 0.63 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †- P-value <0.05 when group 1 compared with controls. ‡ - P-value <0.05 when 
group 2 compared with controls. §- P-value <0.05 when group 3 compared with controls. ||- P-value <0.05 when group 2 compared with group 1. #- P-value <0.05 when 
group 3 compared with group 1.  **– P-value <0.05 when group 3 compared with group 2. ††– ANOVA Welch (W) test was used. Abbreviations: CKD=Chronic kidney 
disease, IRT=Isovolumic relaxation time, ICT=Isovolumic contraction time, E=Early transmitral mean velocity, A=Late transmitral mean velocity, E/A ratio=E to A ratio. 
ET=Ejection time, Tei=Myocardial performance index. 
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Table 6.4: Tissue phase mapping in CKD 
 Healthy Controls 
(n=20) 
Group 1 CKD 
(n=40) 
Group 2 CKD 
(n=40) 
Group 3 CKD 
(n=20) 
p-value 
Rad S’ (cm/s) 2.7±0.31 2.6±0.24 2.5±0.38‡ 2.4±0.31§ 0.003 
Rad E’ (cm/s) 4.2±0.59 3.6±0.62† 3.4±0.78‡ 3.3±0.53§ <0.001 
Rad A’ (cm/s) 1.3±0.35 1.1±0.34 1.2±0.31 1.2±0.28 0.30 
Long S’ (cm/s) 4.6±1.6 3.9±1.1 3.4±1.3‡ 3.6±1.3 0.009 
Long E’ (cm/s) 7.9±1.5 7.5± 2.0 6.7±1.8 6.8±1.4 0.046 
Long A’ (cm/s) 2.3±0.71 2.5±1.1 2.7±0.85 2.5±0.64 0.61 
Long E’/A’ ratio* 3.4±1.3 3.2±1.6 2.6±1.4|| 2.8±1.3 0.003†† 
Long E/E’ ratio* 6±1.2 6.7±1.3 7.5±1.4‡ 7.3±1.4 0.03 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †- P-value <0.05 when group 1 compared with controls. ‡ - P-value <0.05 when group 2 compared with 
controls. §- P-value <0.05 when group 3 compared with controls. ||- P-value <0.05 when group 2 compared with group 1. #- P-value <0.05 when group 3 compared with group 1.  **– P-value <0.05 
when group 3 compared with group 2. ††– ANOVA Welch (W) test was used. Abbreviations: CKD=Chronic kidney disease, Rad=Radial, Long=Longitudinal, S’=Systolic myocardial velocity, 
E’=Early diastolic myocardial velocity, A’=Late diastolic myocardial velocity, E’/A’=E’ over A’ ratio, E/E’=E over E’ ratio.
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However, both MVR and CKD group were independent predictors of IRT in a 
multi-variable ANOVA model, after adjusting for age and sex (p=0.007 and 
0.005 respectively). There were no differences in ICT, ET or Tei index 
between the groups. Mitral E and A velocities and E/A ratio were also normal 
in CKD. 
 
6.4.4 Tissue phase mapping  
 
Radial and longitudinal S’ velocities (markers of systolic contraction) were 
reduced in CKD (Table 6.4). Radial S’ negatively correlated with MBP (rho=-
0.22, p=0.016) and DBP (rho=-0.37, p<0.0001 – Figure 6.2), but not SBP 
(p=0.52). Conversely, longitudinal S’ did not significantly correlate with any 
blood pressures.  
 
A multivariate ANOVA model was created to study the effects of blood 
pressure and CKD on radial systolic velocities. In this model, both DBP (BP 
with highest univariate correlation) and CKD group were independent 
predictors of radial S’ (p=0.02 and 0.01 respectively). Radial S’ also 
significantly correlated with LVEF (rho=0.24, p=0.009 - Figure 6.2), but there 
was no association between LVEF and longitudinal S’ (p=0.24). 
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Figure 6.2: Relationship between tissue phase mapping indices and 
conventional measures of cardiac function: (a) Radial systolic 
myocardial velocity (Rad S') versus diastolic blood pressure (DBP), (b) 
Rad S' versus ejection fraction. The 95% confidence interval of the 
predicted mean is illustrated by the grey zone. 
 
Radial and longitudinal E’ velocities (markers of LV relaxation and stiffness) 
were also reduced in CKD. This difference remained significant after 
adjustment for age and sex. Radial and longitudinal E’ correlated negatively 
with IRT (rho=-0.28, p=0.003 & rho=-0.24, p<0.01 respectively). Unlike IRT, 
neither was associated with MVR (p>0.3). In addition, E’/A’ was reduced and 
E/E’ was raised in CKD (p≤0.046). There were no group differences in radial 
and longitudinal A’ velocities. 
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6.4.5 Association between renal and cardiovascular biomarkers  
 
Worsening eGFR was independently associated with MVR (eGFR β=-0.30, 
p=0.02, R2= 0.14). In addition, anaemia was associated with a reduced radial 
function (Rad S’: Hb β=0.29, p=0.02, R2=0.17, Rad E’: Hb β=0.34, p=0.01, 
R2=0.12). All models were adjusted for age, sex, and use of anti-HTN 
medications. These relationships remained significant after adjusting for the 
effect of afterload (SBP, DBP or MBP). There were no other significant 
relationships between eGFR, PTH and HB with other CV parameters. 
 
6.5 Discussion  
 
In this study, I have investigated the cardiac phenotype in pre-dialysis 
paediatric CKD using CMR. The main findings were that children with CKD 
had: i) Elevated blood pressure (primarily MBP and DBP), ii) Higher LV mass 
volume ratio independent of blood pressure, iii) Abnormalities of diastolic 
function suggestive of reduced active relaxation and increased chamber 
stiffness and iv) Reduced systolic velocities with preserved global systolic 
function.  
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6.5.1 LV remodelling in CKD 
 
I demonstrated that paediatric CKD was associated with concentric 
remodelling as evidenced by increased LV mass volume ratio. Height indexed 
LV mass was not statistically different in this population, unlike previous 
echocardiographic studies. This may be due to the well-recognized 
overestimation of LV mass using echocardiography, particularly in patients 
with renal disease (39).  
 
Ventricular remodelling in these children is partly explained by their 
hypertensive phenotype. However, CKD still remains a predictor of MVR after 
controlling for BP, implying that uraemia-related processes are involved. This 
is important as LVH confers significantly increased cardiovascular risk (96). 
Anaemia and hyperparathyroidism have been suggested as possible causes 
of hypertrophy in CKD (100). Chronic anaemia is associated with increased 
cardiac stress through tachycardia and increased stroke volume, resulting in 
LVH (101). Parathyroid hormone is thought to have a direct trophic effect on 
cardiac myocytes (102). Identification of the exact stimulus may provide new 
targets for therapeutic intervention.  
 
6.5.2 Diastolic function in CKD 
 
In this study, conventional mitral inflow E/A was normal in children with CKD. 
However, both IRT and E’ were abnormal, pointing towards subtle diastolic 
dysfunction in these patients. Isovolumic relaxation time is a marker of active 
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myocardial relaxation and correlates with invasively measured isovolumic 
relaxation constant (99). Previous studies in adults have shown that active 
relaxation is associated LV mass (103) and my findings are in keeping with 
this. However, even after controlling for MVR, CKD remains a predictor of 
IRT. Thus, CKD must exert an independent effect possibly mediated through 
abnormal energy or calcium handling. This could be due to relative oxygen 
deficit in the myocardium arising from a mismatch between myocyte and 
capillary as demonstrated in animal models (104). Blood capillary supply is 
thought to be insufficient in hypertrophied hearts and this contributes to risk of 
myocardial ischaemia, which may result in impaired relaxation. 
 
Early diastolic peak velocity is a marker of both active relaxation and 
ventricular compliance (105). My demonstration of lower E’ measured using 
TPM is in keeping with a previous small study in paediatric CKD (106). In this 
study, E’ did not correlate with MVR or LVMht2.7. Thus, reduced early filling 
cannot simply be explained by LV hypertrophy. One explanation for reduced 
ventricular compliance is myocardial fibrosis, which has been demonstrated in 
several animal models (107). Unfortunately, it is not possible to perform post 
contrast T1 mapping in these patients due to the risk of nephrogenic systemic 
fibrosis (108). Nevertheless, non-contrast methods such as native T1 
mapping are now available (108) and these could be useful to quantify fibrosis 
in CKD in future studies.  
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6.5.3 Systolic function in CKD 
 
Global systolic function was preserved in CKD patients with normal LVEF. 
However, both radial and longitudinal S’ were reduced implying some element 
of systolic dysfunction. These findings are in keeping with previous tissue 
Doppler imaging and echocardiographic strain studies and illustrate the 
importance of assessing systolic function in a more sophisticated manner (23, 
28). The most obvious explanation for reduced S’ is that increased blood 
pressure limits contraction through the force velocity relationship. However, 
only radial S’ negatively correlated with blood pressure and CKD was still a 
predictor of radial S’ after controlling for BP. Thus, CKD specific factors must 
also be involved, which is consistent with the idea of ‘uraemic’ 
cardiomyopathy. Possible biochemical causes include: uraemia induced 
coronary microvascular disease (109) and renal hyperparathyroidism causing 
cardiac fibrosis (110). Importantly, the ability to detect subtle systolic 
dysfunction may allow better risk stratification for these patients.  
 
6.5.4 Renal and cardiovascular biomarkers  
 
I was not able to demonstrate a relationship between eGFR and CV indices 
(apart from MVR), which may be due to the limited number of subjects with 
recent blood tests. Despite that, CKD severity and anaemia (a complication of 
renal disease) were clearly associated with CV abnormalities. Hence, this 
may suggest that CV impairment is mainly conferred by the diagnosis of CKD 
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(and anaemia) rather than renal deterioration.  Future large studies are 
needed to confirm this. 
 
6.5.5 The use of CMR for cardiac assessment in CKD 
 
I have demonstrated that children with CKD exhibit a specific, but subtle 
cardiac phenotype. To evaluate the cardiac phenotype, cardiac timing 
intervals, myocardial velocities and LV mass must be measured. This is 
possible using echocardiography, which has been successfully performed in 
several previous studies (27, 28). However, echocardiography has several 
limitations including overestimation of LV mass (39) and an inability to 
measure myocardial velocities throughout the ventricle. Cardiovascular MR 
does not suffer from these limitations and could have an important role to play 
in phenotyping these patients. Furthermore, new fast imaging techniques 
enable volumetric analysis, inflow assessment and measurement of 
myocardial velocities to be performed quickly and without long breath holds. 
In addition, CMR provides reference standard assessment of aortic flow and 
this allows the vascular phenotype to also be evaluated. Thus, CMR 
represents a clinically feasible method of comprehensively phenotyping 
children with CKD.  
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6.6 Limitations 
 
The main limitation of this study is the lack of patient numbers in each of the 
CKD stages. Despite this, I was able to demonstrate a worsening CV 
impairment with increasing renal dysfunction. Future larger studies with 
greater sampling of patients in each CKD stage will be useful to determine if a 
linear relationship exists between renal severity and CV impairment. Finally, 
performing an echocardiogram in tandem may also have been informative for 
the comparison of CMR findings with an established standard clinical 
investigation. Unfortunately, this was not carried out in order to minimise 
disruption and inconvenience to these patients.  
 
Circumferential myocardial velocities were not examined in this study. This is 
because this parameter has not been validated using the present TPM 
sequence - only radial and longitudinal velocities have been validated (59). 
Assessment of circumferential function and LV torsion may be informative in 
this population where myocardial impairment is subtle. Future studies should 
consider evaluating circumferential motion in addition to radial and 
longitudinal function for a more comprehensive evaluation of myocardial 
function. 
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6.7 Conclusion 
 
In this study, I have shown that CMR can be used to comprehensively 
evaluate cardiac phenotype in children with CKD. Paediatric CKD is 
associated with subtle systolic and diastolic impairment. The novel CMR 
indices used in this study may be useful for identifying high-risk paediatric 
CKD patients. However, more work is needed to determine normative values. 
Future prospective studies will also be required to correlate these markers 
with prognosis in order to predict cardiovascular risk.  
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7 Cardiovascular effects of renovascular 
hypertension 
 
In this chapter, I will describe the comprehensive evaluation of the 
cardiovascular phenotype in children with renovascular hypertension and 
determination of how that may differ in essential hypertension. 
 
7.1 Personal contribution 
 
For the study described in this chapter:  
 I completed the ethics application process. 
 I recruited all subjects.  
 I acquired, collated, and tabulated the relevant clinical data.  
 I completed the segmentation and data analysis on all study subjects.   
 I performed statistical analysis on the study dataset. 
 
7.2 Introduction 
 
Renovascular hypertension (RH) is associated with high cardiovascular 
mortality in adults (31). This is because adult renal artery stenosis (RAS) is 
typically atherosclerotic in origin and associated with conventional CV risk 
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factors (33). In contrast, the long-term CV risk of RAS in children is unknown. 
The CV effects of RAS have never been characterized in children.  
 
Any CV abnormalities that arise are thought to be mainly due to the effect of 
hypertension as paediatric RAS is seldom associated with other CV risk 
factors. Thus, the main therapeutic goal in paediatric RH is to normalize blood 
pressure using aggressive pharmacological treatment, renal artery 
angioplasty, or surgical revascularization (33). Good BP control is frequently 
achieved and complete resolution of hypertension is sometimes possible 
(111, 112). Because of this, paediatric RH is widely regarded as “reversible” 
compared to idiopathic essential hypertension (eHTN). However, it is not 
known if CV effects persist after successful treatment of RH in children. 
 
Two-dimensional echocardiography is conventionally used to assess for CV 
changes associated with hypertension. However, as previously mentioned, 
ECHO has known limitations such as inaccurate left ventricular (LV) mass 
measurements and poor reproducibility (22), particularly in patients with poor 
acoustic windows (113).  
 
Cardiac magnetic resonance imaging is the reference standard method for 
quantification of ventricular mass and volume mass and is thus ideal for 
assessment of hypertensive changes in paediatric RH (77). Measurement of 
cardiac timings, mitral diastolic flow and longitudinal and radial myocardial 
velocity is also now possible due to recent CMR technological advancements 
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(57, 59). Thus, subtle changes to myocardial structure and function such as 
diastolic dysfunction may now be reliably assessed using CMR (57). 
 
The objective of this study was to characterize cardiovascular structure and 
function in a cohort of optimally treated paediatric RAS, using CMR. The 
findings in RAS will be compared with a cohort of treated idiopathic 
hypertension patients and healthy controls.  
 
7.3 Methods 
 
7.3.1 Study Population 
 
The study population consisted of 45 children in total: 15 children with a 
diagnosis of renovascular hypertension, 15 children with idiopathic essential 
hypertension and 15 healthy controls.  
 
A diagnosis of RAS was confirmed with a combination of non-invasive and 
invasive investigations including renal vessel Doppler ultrasound scan, renal 
scintigraphy, renal vein renin sampling or renal angiography (33). The optimal 
treatment plan of all RH children was recommended following discussion at 
the GOSH renal artery stenosis multidisciplinary team (MDT) meeting 
comprising of paediatric nephrologists, surgeons and interventional 
radiologists. Only patients with stable optimally treated RH after completing 
recommended treatment were recruited.  
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The eHTN patients were clinically evaluated according to published 
recommendations to exclude secondary causes of HTN (79). Exclusion 
criteria were: i) age <7 or >18 years, ii) congenital structural heart disease or 
primary myocardial disease, iii) chronic kidney disease greater than stage 2 or 
deteriorating renal function, iv) active vasculitis v) cardiac arrhythmia, vi) 
medical devices precluding CMR, vii) presence of an alternative diagnosis for 
hypertension apart from RH (in the RH cohort), and viii) current or previous 
renal replacement therapy.  
 
The last available blood test (full blood count, urea, creatinine, electrolytes) 
performed as part of their outpatient care was retrieved for the RAS and 
eHTN participants. Renal function was estimated by the modified Schwartz 
formula to obtain the estimated glomerular filtration rate (eGFR) and CKD 
stage. The medical notes were also reviewed specifically to confirm that the 
current documented renal function is stable and there is no clinical suspicion 
of renal deterioration.  
 
7.3.2 Study protocol 
 
The study protocol has been previously outlined in detail in Chapter 4. In 
summary, I performed non-invasive blood pressure measurements, and 
assessment of left ventricle (SAX LV stack acquisition using KT-SENSE 
sequence), aortic flow (acquired in ascending aorta using retrospective-gated, 
spiral SENSE PCMR sequence), cardiac timing (acquired at the LV 
inflow/outflow SAX position using real-time UNFOLD-SENSE spiral PCMR 
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sequence) and myocardial velocity (acquired in Mid LV SAX position using 
self-navigated golden-angle spiral TPM sequence). This was used to calculate 
LV mass and volume, aortic flow, cardiac timing and myocardial velocity 
measures as described below.   
 
7.3.3 Statistics 
 
Statistical analyses were performed using Stata 13 (StataCorp, College 
Station, Texas, USA). Data were examined for normality using Shapiro-Wilk 
normality test and non-normally distributed data was transformed using a 
zero-skewness log transform to ensure normal distribution prior to analysis. 
Descriptive statistics were expressed as mean (± standard deviation) or 
geometric mean (± geometric standard deviation) if data was log transformed. 
Chi-squared test was used to determine if sex distribution between groups 
were different. To assess for CV changes in RH patients, comparisons 
between RH, eHTN and healthy controls were made. Between group 
differences were assessed using analysis of variance (ANOVA). Levene’s test 
was used to assess for homogeneity of variances across the groups and 
Welch’s correction was applied for non-homogeneous variance. To 
interrogate differences between each group, a post-hoc pairwise comparison 
was performed on parameters significantly different on ANOVA testing. The 
Bonferroni method was used to adjust for potential Type 1 errors in the 
pairwise comparisons. To determine if potential confounders may explain the 
significant differences, indexed SVR/TAC and MVR models were adjusted for 
sex, while diastolic indices, were adjusted for age and sex. A p value < 0.05 
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was considered statistically significant. Indices not statistically different to 
healthy subjects have been described as ‘normal’. 
 
7.4 Results 
 
7.4.1 Demographics 
 
The CMR scan was well tolerated by all the children. All subjects had 
sufficient image quality and none were excluded. Blood results were available 
in all except in two eHTN subjects (Table 7.1). Some patients (n=12) had 
blood tests performed greater than 12 months from the CMR scan. However, 
as clinical status and renal function were stable in all patients, the blood 
results were deemed reflective of their baseline function. All subjects had 
eGFR>90 ml/min/1.73 m2, apart from 5 RAS and 3 eHTN patients who had 
eGFR >74 ml/min/1.73 m2.  
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Table 7.1: Demographics and baseline characteristics of study population. 
 Controls 
n=15 
RH 
n=15 
eHTN 
n=15 
P-value 
Age (years)* 12±1.3 12±1.3 14±1.3 0.11 
Sex (% male) 53% 73% 80% 0.26 
Height (cm) 156±14 156±18 164±14 0.31 
Weight (kg)* 50±1.3 48±1.4 64±1.4§ 0.029 
Body Mass Index (kg/m2) 21±2.3 20±3.6 25±5.5 0.07|| 
Body Surface Area (m2) 1.5±0.24 1.5±0.35 1.7±0.34 0.045 
Hemoglobin (g/L) - 129±9.7 141±14 0.017 
Hematocrit (L/L) - 0.37±0.031 0.41±0.04 0.012 
Mean Corpuscular Volume (fL) - 81±3.6 78±8.4 0.77|| 
Platelet count (x109/L) - 279±76 246±51 0.23 
White Cell Count (x109/L) - 7.4±2.5 6.9±1.7 0.55 
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Sodium (mmol/L) - 143±1.8 142±2.3 0.86 
Potassium (mmol/L)* - 4.2±1.1 4±1.1 0.24 
Urea (mmol/L) - 4.8±0.99 4.3±0.89 0.25 
Creatinine (umol/L) - 51±18 61±14 0.12 
Medications (%)     
ACE or AT2 Inhibitor - 20% 53% - 
Beta-Blocker - 33% 13% - 
Calcium Channel Blocker - 40% 53% - 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †-  P-value <0.05 when RH compared with controls. ‡ - P-value <0.05 when 
eHTN compared with controls. §-  P-value <0.05 when RH compared to eHTN. ||- ANOVA Welch (W) test was used. Abbreviations: RH=Renovascular hypertension 
group, eHTN=Essential hypertension group, ACE=Angiotensin converting enzyme, AT2=Angiotensin 2 receptor.  
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All RH patients had objective evidence of RAS, while 6 had bilateral RAS. 
Optimal treatment recommended by the MDT had been completed at the time 
of the CMR scan and none were awaiting any further invasive treatment. All 
had been treated with angioplasty (7 patients underwent two or more 
angioplasty attempts), except for 4 who were either medically managed (n=2) 
or had a unilateral nephrectomy (n=2). In addition, one patient received 
ethanol embolization of a small branch of the renal artery (RA). 
 
Three patients underwent surgical revascularization; one was successful on 
the second surgical attempt while two had sub-optimal surgical results and 
required a nephrectomy (n=1) or optimal medical therapy (n=1). They 
continued to be followed up either at GOSH or at their local hospital. Prior to 
recruitment, all patients had been deemed by their clinicians (at the last 
clinical consultation) to have optimally controlled hypertension with clinically 
stable BP. 
 
At the time of the CMR, 6 RAS children were no longer on anti-HTN therapy. 
Of the 9 who received anti-HTN medication, 5 were taking two or more drugs. 
Other significant medical history is listed in Table 7.2. Of note, two patients 
had mild mid-aortic syndrome, which was deemed not clinically significant and 
managed conservatively. 
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Table 7.2: Associated co-morbidities of study population. 
 Associated co-morbidities No. of patients / (%) 
Renovascular Hypertension Fibromuscular dysplasia 1 (7%) 
 Previous embolic stroke 2 (13%) 
 Mild mid-aortic arch syndrome 2 (13%) 
 Asthma 3 (20%) 
 Neurofibromatosis 3 (20%) 
 Coeliac disease 1 (7%) 
Essential Hypertension Previous intracerebral bleed 1 (7%) 
 C6 complement deficiency 1 (7%) 
 Asthma 2 (13%) 
 Neurofibromatosis 1 (7%) 
 G6PD deficiency 1 (7%) 
 Epilepsy 1 (7%) 
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All eHTN patients had a diagnosis of idiopathic hypertension and received 
anti-HTN medication, apart for one child whose medication was temporarily 
stopped for 2 weeks while awaiting an investigation. Five patients were on 2 
anti-HTN medications. All eHTN patients (apart from the child awaiting 
investigation) were deemed to have optimally controlled BP when last 
reviewed in the outpatient clinic. The healthy subjects had no significant past 
medical history and were not on any medications. 
 
There was no difference in sex, age or BSA between RAS and controls (Table 
7.1). However, weight was significantly greater in the eHTN compared to RAS 
patients, reflecting the slight preponderance for older boys in primary 
hypertension. 
 
7.4.2 Vascular function 
 
Systolic and diastolic BP (including SBP and DBP centiles) were significantly 
elevated in RAS (p≤0.02) and eHTN (p≤0.003) compared to controls (Table 
7.3).  Nevertheless, there was no difference in SBP, DBP and MBP (including 
BP centiles) between eHTN and RAS (p>0.19). 
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Table 7.3: Vascular phenotype of study population. 
 Controls  
n=15 
RH  
n=15 
eHTN  
n=15 
P-value 
SBP (mmhg)  103±11 122±8.4† 129±12‡ <0.001 
DBP (mmhg)  52±6.6 63±12† 68±11‡ <0.001 
MBP (mmhg)  74±5.9 88±8.6† 93±10‡ <0.001 
PP (mmhg) 51±12 59±13 61±9.2 0.058 
SBP percentile* 25±2.5 80±1.3† 83±1.3‡ <0.001|| 
DBP percentile 22±14 50±31† 56±30‡ <0.001|| 
CO (l/min/m2)* 3.7±1.2 3.6±1.2 4±1.2 0.30 
SVR (WU.m2)* 20±1.2 25±1.3† 23±1.2 0.018 
TAC (ml/mmHg. m2.102) 59±14 50±11 45±5.4‡ 0.004|| 
AoS (%)* 50±1.7 36±1.9 45±1.7 0.30 
AoC (cm2.mmHg-1.10-2)* 3.2±1.5 1.7±1.5† 2.2±1.5‡ <0.001 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †-  P-value <0.05 when RH compared with controls. ‡ - P-value <0.05 when eHTN compared with controls. §-  P-value <0.05 when 
RH compared to eHTN. ||- ANOVA Welch (W) test was used. Abbreviations: RH=Renovascular hypertension group, eHTN=Essential hypertension group, SBP=Systolic blood pressure, DBP=Diastolic blood pressure, 
MBP=Mean blood pressure, PP=pulse pressure, CO=Cardiac Output, SVR=Systemic vascular resistance, TAC=Total arterial compliance, AoS=Ascending aortic strain, AoC=Ascending aortic compliance.
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Systemic vascular resistance was significantly elevated in RAS compared to 
controls (p≤0.02), as can be seen in Figure 7.1. Total arterial compliance was 
also mildly reduced compared to controls, although this did not reach 
statistical significance (p=0.06).  
 
 
 
Figure 7.1: Bar chart showing differences in SVR between groups:  SVR 
is significantly (p<0.05) higher in Renovascular hypertension compared 
to healthy controls. Abbreviations: SVR=systemic vascular resistance. 
 
 
 138 
 
 
 
Figure 7.2: Bar chart showing differences in TAC between groups: TAC 
is significantly (p<0.05) lower in eHTN compared to healthy controls. 
Abbreviations: TAC=total arterial compliance. 
 
Conversely, the eHTN cohort had a significantly lower TAC compared to 
controls (p=0.003), as seen in Figure 7.2. Despite that, there was no statistical 
difference in TAC or SVR between RAS and eHTN (p=0.76, p=1.00 
respectively). In addition, AoC was significantly lower in RAS and eHTN 
compared to controls. There were no significant differences in CO, SV or AoS 
between all groups. 
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The SVR, TAC and AoC relationships remained significant even after 
correcting for sex and age. 
 
7.4.3 Cardiac structure and global function  
 
Left ventricular MVR, a marker of LV remodeling, was significantly elevated in 
RAS and eHTN compared to controls (p=0.04). However, there was no 
difference between RAS and eHTN (Table 7.4). Although some significance 
was lost after adjustment for sex, there was still a trend for elevated MVR in 
the RAS group (p=0.078). Although LVMHT2.7 appeared elevated in RAS and 
eHTN, they did not reach statistical significance (p=0.82, p=0.09) when 
compared with controls. There were also no differences in EDV and ESV 
between all groups.  
 
 
 140 
Table 7.4: Left ventricular assessment. 
 Controls 
n=15 
RH 
n=15 
eHTN 
n=15 
P-value 
LVEDV (ml/m2) 74±9.4 69±9.3 70±9.3 0.28 
LVESV (ml/m2) 23±4.2 19±7.8 22±5.4 0.14 
LVSV (ml/m2) 51±6.3 49±7.9 48±5.4 0.40 
Heart Rate (BPM) 74±13 73±11 85±15§ 0.02 
LVMht2.7 (g/m2.7)  23±2.9 25±5.4 27±6.6 0.09 
MVR (g/ml) 0.69±0.091 0.81±0.15† 0.83±0.14‡ 0.008 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †-  P-value <0.05 when RH compared with controls. ‡ - P-value <0.05 when 
eHTN compared with controls. §-  P-value <0.05 when RH compared to eHTN. Abbreviations: RH=Renovascular hypertension group, eHTN=Essential hypertension 
group, LVEDV=Left ventricular end-diastolic volume, LVESV=Left ventricular end-systolic volume, LVSV=Left ventricular stroke volume, LVMHT(2.7)=Left ventricular 
mass corrected by height to the power of 2.7. MVR=Left ventricular mass volume ratio.  
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Table 7.5: Left ventricular global systolic and diastolic function assessment. 
 Controls 
n=15 
RH 
n=15 
eHTN 
n=15 
P-value 
EF (%) 69±3.4 73±9.1 69±4.4 0.46|| 
IRT (ms) 64±11 67±11 68±14 0.58 
ICT (ms) 47±15 54±27 47±22 0.8|| 
Mitral E flow (mls) 47±9.6 57±11† 48±10 0.02861 
Mitral A flow (mls) 19±4.2 25±6.6† 23±5.5 0.037 
E/A ratio* 2.5±1.2 2.3±1.4 2.1±1.3 0.38 
ET (ms) 278±19 276±22 266±15 0.18 
Tei 0.4±0.081 0.44±0.13 0.43±0.11 0.54 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †-  P-value <0.05 when RH compared with controls. ‡ - P-value <0.05 when 
eHTN compared with controls. §-  P-value <0.05 when RH compared to eHTN. ||- ANOVA Welch (W) test was used. Abbreviations: RH=Renovascular hypertension 
group, eHTN=Essential hypertension group, EF=Ejection fraction, IRT=Isovolumic relaxation time, ICT=Isovolumic contraction time, E=Early transmitral mean velocity, 
A=Late transmitral mean velocity, E/A ratio=E to A ratio, ET=Ejection time, Tei=Myocardial performance index.  
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Global systolic and diastolic function was preserved in RAS and eHTN 
patients. Left ventricular EF, E/A ratio, isovolumic relaxation time and 
myocardial performance index were all normal in both groups (Table 7.5). 
 
7.4.4 Myocardial mechanics 
 
There was impairment of longitudinal relaxation in RAS and eHTN (Table 7.6). 
Longitudinal E’/A’ were both similarly reduced in RAS and eHTN (p≤0.035). In 
addition, there was a trend towards an elevated E/E’ in the RAS group 
compared to controls (p=0.098). The E/E’ ratio was significantly lower in 
eHTN compared to RAS patients (p<0.001). There was no impairment of 
longitudinal systolic function or radial mechanics in the RAS cohort. These 
differences remained significant even after adjusting for sex and age. 
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Table 7.6: Myocardial velocity assessment. 
 Controls 
n=15 
RH 
n=15 
eHTN 
n=15 
P-value 
Rad S’ (cm/s) 2.7±0.41 2.6±0.27 2.9±0.27§ 0.04 
Rad E’ (cm/s) 4±0.85 4±0.7 3.8±0.5 0.77 
Rad A’ (cm/s) 1.3±0.39 1.2±0.4 1.3±0.31 0.68 
Long S’ (cm/s)* 4.1±1.4 3.3±1.5 3.8±1.2 0.17 
Long E’ (cm/s) 7.6±1.9 7.3±1.9 9.5±1.7‡§ 0.004 
Long A’ (cm/s) 2.2±0.49 2.7±0.87 3.6±0.76‡§ <0.001 
Long E’/A’ ratio 3.5±0.7 2.8±0.67† 2.7±0.66‡ 0.006 
Long E/E’ ratio 6.6±2 8.2±2.3 5.3±1.3§ <0.001 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †-  P-value <0.05 when RH compared with controls. ‡ - P-value <0.05 when 
eHTN compared with controls. §-  P-value <0.05 when RH compared to eHTN. Abbreviations: RH=Renovascular hypertension group, eHTN=Essential hypertension 
group, Rad=Radial, Long=Longitudinal, S’=Systolic myocardial velocity, E’=Early diastolic myocardial velocity, A’=Late diastolic myocardial velocity, E’/A’=E’ over A’ ratio, 
E/E’=E over E’ ratio.  
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7.5 Discussion  
 
In this study, I assessed the cardiovascular effects in optimally treated 
renovascular hypertension in children.  The key findings were: i) The vascular 
phenotype in paediatric RH was principally defined by an elevated SVR, while 
essential hypertension was characterized by reduced TAC, ii) Left ventricular 
remodelling and diastolic impairment was evident in the RAS cohort despite 
having received optimal treatment, and iii) Left ventricular changes were no 
different between treated RAS and eHTN children.  
 
It is increasingly recognised that differences in the pattern of HTN is 
associated with differential mortality risk (114). Systolic and diastolic HTN in 
young adults, which is associated with an elevated systemic vascular 
resistance, has been shown to be associated with the highest risk when 
compared to other patterns of HTN such as isolated systolic HTN (114). 
Indeed, the pattern of HTN is closely related to the vascular phenotype (115). 
I found that an elevated SVR was the primary haemodynamic abnormality in 
renal artery stenosis. In addition, RAS patients were euvolaemic as CO and 
EDV, surrogates of volume status, were both normal.  
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Thus, abnormal vascular function is likely to be the main mechanism for 
elevated BP in RAS. This is consistent with current understanding (116). 
Renal artery stenosis results in renal ischaemia, which in turn lead to wide 
ranging maladaptive neurohumoral and vascular responses. Vasoconstriction 
is primarily mediated through renin-angiotensin-aldosterone axis activation 
and increased sympathetic activity in renovascular hypertension (116, 117).  
 
An elevated SVR leads to increase in mean intraluminal pressure (i.e. high 
MBP). Given the viscoelastic properties of the aortic wall, an increase in 
intraluminal pressure results in aortic wall stiffening (115).  This may explain 
the finding of mildly reduced local aortic compliance (reduced AoC) in the 
RAS group. Nonetheless, it was not sufficient to cause any discernible effect 
on TAC. This study demonstrates that vascular phenotype in RAS is different 
to essential hypertension where increased aortic wall stiffness appears to be 
the principal feature.  
 
The finding that SVR is high in RAS children despite having received optimal 
treatment is significant for two reasons. Firstly, it shows that although 
renovascular hypertension is eminently treatable, it is not completely 
“reversible”. Given that elevated systolic and diastolic pressures are a 
predictor of increased CV risk (114), the systolic and diastolic hypertension in 
RAS suggests that these children may have increased mortality risk. This will 
need to be investigated in future studies.  
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Secondly, although treatment of renal artery stenosis removes the most 
obvious causes of neurohumoral activation, these results indicate that 
peripheral vasoconstriction persists in treated patients. In most cases, this is 
likely due to the presence of residual renal lesions not amenable to further 
invasive procedures, causing persistent neurohumoral activation. However, it 
is also possible that the vascular remodelling or dysfunction that was present 
pre-treatment failed to normalize post-treatment. Nevertheless, optimal 
treatment of RH may require more aggressive use of vasodilators to 
counteract the elevated SVR. 
 
Finally, the presence of myocardial involvement in RH and eHTN children is 
important. Although BP was adequately treated (below 90th centile), it 
remained significantly elevated compared to healthy controls. Consequently, 
LV remodelling and sub-clinical diastolic impairment were present in both 
groups and are early markers of hypertensive heart disease (118). This 
suggests that while current RAS therapies may be effective at reducing BP, it 
may only mitigate from the worse effects of hypertension. Therefore, these 
children continue to be at risk of hypertensive heart disease despite receiving 
treatment. This study provides evidence that children with renovascular 
hypertension need to be continually followed up and may require more 
aggressive treatment to achieve a lower target blood pressure.  
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7.6 Limitations 
 
The main limitation of this study is the limited number of RAS patients. Renal 
artery stenosis is a relatively rare condition and commonly associated with 
significant renal impairment and other comorbidities. As renal impairment and 
other conditions such as significant mid-aortic syndrome were potential 
confounders, it was important that only a “pure” population of RAS were 
included into the study. Hence, it was not possible to recruit a large number of 
RAS children from a single-centre. However, in spite of that, I was able to 
demonstrate a significant difference in cardiovascular structure and function 
between RAS and healthy controls. Future studies will need to consider multi-
centre recruitment to increase the study population. 
 
7.7 Conclusion 
 
In this study, I have shown that SVR remains a key feature in optimally 
treated renovascular hypertension in contrast to treated essential 
hypertension where aortic stiffness is dominant. In addition, these treated 
children continue to display evidence of diastolic impairment. Future studies 
are needed to determine if this difference in vascular phenotype may confer a 
greater CV risk in the long term. 
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8 The effect of dialysis on cardiovascular function  
 
In this chapter, I will describe the exploratory study I undertook to investigate 
the potential utility of CMR for the CV assessment of children on dialysis. This 
involved the comprehensive evaluation of the cardiovascular phenotype in 
children receiving dialysis and determination of how that may relate with 
different dialysis modalities. 
 
8.1 Personal contribution 
 
For the study described in this chapter:  
 I completed the ethics application process. 
 I recruited all subjects.  
 I acquired, collated, and tabulated the relevant clinical data.  
 I completed the segmentation and data analysis on all study subjects.   
 I performed statistical analysis on the study dataset. 
 
8.2 Introduction 
 
Children on dialysis have a high cardiovascular disease burden (119). 
Cardiovascular mortality is a major cause of death in paediatric end stage 
renal failure (ESRF). The highest mortality rates are observed in children on 
maintenance dialysis (4, 120). Unfortunately, there has been minimal 
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improvement over the past decades (8). This is partly because the CV 
disease in paediatric ESRF is difficult to identify. One of the obstacles to 
improving CV outcomes in this population is the lack of good imaging 
biomarkers to identify early CV impairment and guide treatment. 
 
Conventional measures of global cardiac function such as left ventricular 
ejection fraction have limited utility as a biomarker as it is frequently normal in 
dialysis patients (9, 121). Nonetheless, like the pre-dialysis population, 
dialysis patients also have left ventricular hypertrophy and abnormal systolic 
and diastolic function (24, 27, 122). Vascular abnormalities such as arterial 
calcification and stiffness are thought to be particularly marked in dialysis (14, 
69, 123).  This in turn leads to an increase in afterload causing hypertension 
(124) and related myocardial effects (125). Thus, accurate measurement of 
these abnormalities and determining the relationship between vascular and 
myocardial dysfunction may be especially important in this population.  
 
Two-dimensional echocardiography is used for the cardiac assessment of 
renal patients. As previously mentioned, ECHO has limitations such as high 
inter- and intra-observer variability (22) and is unable to perform vascular 
assessment. Vascular function may be assessed with pulse wave velocity 
measurement. As such, comprehensive cardiovascular assessment will 
require multi-modality imaging which is expensive and time-consuming. 
Furthermore, non-simultaneous acquisition of myocardial and vascular data 
makes it challenging to investigate the interaction between vascular and 
myocardial abnormalities. 
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Cardiac MRI offers significant advantages over ECHO (22), not least the 
ability to provide simultaneous assessment of vascular and myocardial 
function. In addition, CMR measures of arterial stiffness such as total arterial 
compliance also have prognostic value (126). As demonstrated in the pre-
dialysis population, new sequences like tissue phase mapping are also able to 
detect subtle abnormalities. Hence, using CMR to characterise the CV 
phenotype in the two main forms of dialysis may offer a better insight into the 
disease process and even yield new potential biomarkers.  
 
The aims of this study are to: 
 
1. Define the cardiovascular characteristic in haemodialysis and peritoneal 
dialysis population using CMR and, 
2. Determine how specific vascular characteristics associated with dialysis 
may affect myocardial function. 
 
8.3 Methods 
 
8.3.1 Study Population 
 
The study population consisted of four groups of children, patients receiving 
in-centre haemodialysis (HD) or automated peritoneal dialysis (PD), pre-
dialysis end-stage renal failure children and healthy controls. All patients were 
recruited from Great Ormond Street Hospital renal outpatient clinics, while 
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healthy children were recruited through hospital advertisements. Recruitment 
was carried out from June 2015 to October 2016. Exclusion criteria were: i) 
age <7 or >18 years, ii) congenital structural heart disease or primary 
myocardial disease, iii) active vasculitis iv) cardiac arrhythmia, v) intercurrent 
illness, vi) clinical symptoms of heart failure and viii) medical devices 
precluding CMR. 
 
Medical history and current medications were obtained from medical notes 
and checked with parents and subjects on the day of the study. The last 
available blood test (full blood count, urea, creatinine, electrolytes) performed 
was retrieved for all CKD participants. Renal function was estimated by the 
modified Schwartz formula to obtain the estimated glomerular filtration rate 
(eGFR) and CKD stage. To confirm that the healthy controls had no 
significant medical history, a clinical history (including drug history) was taken 
from the parents of the healthy children. No blood tests were performed in the 
healthy cohort.  
 
Haemodialysis patients were treated three times a week, with standard 
sodium bicarbonate dialysis (Na 138, HCO3 34, K 1.5, Ca 1.25mmol/L) and 
0.6-1.4m2 dialysers, (using either high or medium flux synthetic dialysers). All 
HD patients underwent CMR between 1-2 hours after their dialysis sessions. 
 
All peritoneal dialysis patients were treated with automated cyclical PD 
consisting of ten 1-1.5L automated PD exchanges overnight (fill volume 
between 1.1-1.3L/m2 using a standard dialysate containing glucose) and a 
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daytime dwell (dwell volume between 0.6-1.0L/m2 using a icodextrin (7.5%) 
dialysis solution), apart from one who was receiving tidal peritoneal dialysis. 
All PD patients had their CMR scan more than 3 hours after instillation of the 
daytime dwell fluid. 
 
8.3.2 Study protocol 
 
The study protocol has been previously outlined in detail in Chapter 4. In 
summary, I performed non-invasive blood pressure measurements, and 
assessment of left ventricle (SAX LV stack acquisition using KT-SENSE 
sequence), aortic flow (acquired in ascending aorta using retrospective-gated, 
spiral SENSE PCMR sequence), cardiac timing (acquired at the LV 
inflow/outflow SAX position using real-time UNFOLD-SENSE spiral PCMR 
sequence) and myocardial velocity (acquired in Mid LV SAX position using 
self-navigated golden-angle spiral TPM sequence). This was used to calculate 
LV mass and volume, aortic flow, cardiac timing and myocardial velocity 
measures as described below.   
 
8.3.3 Statistics 
 
Statistical analyses were performed using Stata 13 (StataCorp, College 
Station, Texas, USA). Data were examined for normality using Shapiro-Wilk 
normality test and non-normally distributed data was transformed using a 
zero-skewness log transform to ensure normal distribution prior to analysis. 
Descriptive statistics were expressed as mean (± standard deviation) or 
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geometric mean (± geometric standard deviation) if data was log transformed. 
Chi-squared test was used to determine if sex distribution between groups 
were different. To assess for CV changes in dialysis patients, comparisons 
were made with pre-dialysis and healthy subjects. Between group differences 
were assessed using analysis of variance (ANOVA). Levene’s test was used 
to assess for homogeneity of variances across the groups and Welch’s 
correction was applied for non-homogeneous variance. To determine if 
potential confounders may explain the significant differences, all significant 
indices (on ANOVA testing) were adjusted for age and sex. A post-hoc 
pairwise comparison was not performed, as patient numbers in each group 
were not sufficient to detect intergroup differences. 
 
Finally, multiple linear regression analysis was undertaken to interrogate the 
relationship between the significant myocardial mechanics indices (on 
ANOVA testing) and BP. The models were adjusted for age and sex. Adjusted 
r2 statistic was used to assess the goodness of fit. The beta coefficient (β) 
was used to evaluate the relationship between the dependent variable and the 
independent factors in the regression model. A p value < 0.05 was considered 
statistically significant. Indices not statistically different to healthy subjects 
have been described as ‘normal’. 
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8.4 Results 
 
8.4.1 Demographics 
 
A total of thirty-seven children were recruited: 9 haemodialysis, 8 peritoneal 
dialysis, 10 pre-dialysis end-stage renal failure patients and 10 healthy 
controls. There was no difference in sex, age or BSA between the groups 
(Table 8.1). Of the 9 HD patients, 5 were dialysed via tunneled line and 4 via 
AV fistula. One patient was awaiting treatment for an AV fistula stenosis and 
received dialysis via a tunneled line. 
 
At the time of the CMR scan, the HD patients were receiving three sessions of 
in-centre conventional haemodialysis a week while PD patients received 
automated cyclical peritoneal dialysis regimen, which consisted of multiple 
cycles of exchanges overnight and a daytime dwell of (mean dwell volume 
938±400mls) instilled from the end of the nocturnal PD session in the morning 
(The presence of peritoneal dwell volume was confirmed on the scout images 
taken at the beginning of the CMR scan). All dialysis patients had been on 
dialysis for greater than 3 months, apart from one HD patient who had only 
been on HD for a month.  
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Table 8.1: Demographics and baseline characteristics of study population. 
 Controls 
n=10 
CKD stage 5 
n=10 
HD 
n=9 
PD 
n=8 
P-value 
Age (years)   12±2.4   13±3.7   11±3   12±3.8  0.73 
Sex (% male) 60% 50% 56% 38% 0.81 
Height (cm)  159±12  145±21  137±18  142±27  0.11 
Weight (kg)*   49±1.3   41±1.5   33±1.3   35±1.6 0.086 
Body Mass Index (kg/m2)   19±2.3   20±2.9   18±3   18±1.7  0.28 
Body Surface Area (m2) *  1.5±1.2  1.3±1.3  1.1±1.2  1.2±1.4 0.092 
Hemoglobin (g/L) -  127±11  115±21  119±15  0.29 
Hematocrit (L/L) -  0.37±0.03 0.34±0.06  0.35±0.04  0.39 
Mean Corpuscular Volume (fL) -   84±4   84±11   85± 6.5  0.90 
Platelet count (x109/L) -  248±64  225±51  247±53  0.64 
White Cell Count (x109/L) -   8.4±2.4  5.7±2.1  7.4±2.3 0.051 
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Sodium (mmol/L) -  142±2.7  138±7.2  139±2.7  0.20 
Potassium (mmol/L) -  4.3± 0.4  4.7±1.2  4.2± 0.49  0.83† 
Urea (mmol/L) -   21±4   15±10   13±2 <0.001† 
Creatinine (umol/L) -  387±109  553±350  643±328  0.26† 
Medications (%)      
ACE or AT2 Inhibitor - 10% 0% 25% - 
Beta-Blocker - 30% 0% 13% - 
Calcium Channel Blocker - 20% 0% 13% - 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †-ANOVA Welch (W) test was used. Abbreviations: CKD=Chronic kidney disease, HD= Haemodialysis 
group, PD=Peritoneal dialysis group, ACE=Angiotensin converting enzyme, AT2=Angiotensin 2 receptor.  
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The duration of current treatment with renal replacement therapy was an 
average of 30 months (30±27months) in HD and average of 9 months 
(9±5months) in PD. All PD patients did not receive any previous RRT prior to 
current PD apart from 2 patients (1 had a previous failed renal transplant and 
1 received 5 months of HD prior to starting current PD). In contrast, the 
majority of HD patients (n=6) had previous failed renal transplants and also 
received either HD or PD prior to their transplant. Only two did not have any 
renal replacement therapy (RRT) prior to current HD regimen, while one 
received PD for 1 month prior to commencing HD.  
 
All pre-dialysis CKD patients had eGFR ≤20ml/min/1.73 m2. The renal 
disease aetiology (or reason for dialysis) and significant co-morbidities in the 
groups are summarised in Table 8.2. None of the healthy controls had any 
significant past medical history and were not on any medications.  
 
The CMR scan was well tolerated by all the children. All subjects had 
sufficient image quality and none were excluded apart from mitral inflow 
velocity data in a PD patient where EA merging due to tachycardia meant that 
EA velocity could not be accurately assessed. Blood results were available in 
all subjects apart from the healthy controls. These are summarised in Table 
8.1.  
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Table 8.2: Summary of renal diagnosis and co-morbidities in the study population. 
 Renal diagnosis/ 
Reason for dialysis 
No. of patients / (%) Co-morbidities No. of patients / (%) 
Haemodialysis Previous transplant failure 6(67%) Asthma 1(11%) 
   Human immunodeficiency virus 1(11%) 
 Miscellaneous causes 3 (33%) Ventriculo-peritoneal shunt 1(11%) 
   Previous hyperthyroidism 1(11%) 
Peritoneal dialysis CAKUT 2(25%) Nil  
 Renal dysplasia 2(25%)   
 Focal segmental glomerulosclerosis 3(38%)   
 Nephrolithiasis 1(7%)   
Pre-dialysis CKD CAKUT 4(44%) Asthma 1(11%) 
 Renal dysplasia 2(22%)   
 Miscellaneous causes 4 (44%)   
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8.4.2 Vascular function 
 
Blood pressure was significantly elevated in dialysis groups compared to 
healthy controls. Diastolic and mean BP were similarly elevated in all CKD 
groups, with a trend towards an increased SBP (p=0.068) (Table 8.3). This 
pattern was also reflected by elevated SBP and DBP centiles. However, there 
was no difference in PP between the groups.  
 
Systemic vascular resistance was significantly elevated in the dialysis groups, 
with the greatest SVR observed in the PD population (p=0.004). Conversely, 
there was no difference in total arterial compliance between the groups 
(p=0.71). There was also no significant difference in measures of local 
(ascending) aorta stiffness like AoC or AoS. Although CO was lower in both 
dialysis groups, this did not reach statistical significance (Table 8.3). However, 
stroke volume was significantly lower in dialysis cohorts with the lowest SV 
observed in the PD group.  
 
Both SVR and SV remained significantly associated with dialysis modality 
even after correcting for sex and age. 
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Table 8.3: Vascular phenotype of study population. 
 Controls 
n=10 
CKD stage 5 
n=10 
HD 
n=9 
PD 
n=8 
P-value 
SBP (mmhg)   104±9.6  118±15  122±19  117±16 0.068 
DBP (mmhg)    50±5.4   72±12   76±14   75±16 <0.001† 
MBP (mmhg)*   73±1.1   89±1.1   93±1.2   90±1.2 <0.001† 
PP (mmhg)   54±13   47±12   46±10   43±9.6 0.22 
SBP percentile*   28±2.2   70±1.6   83±1.4   81±1.2 0.008† 
DBP percentile*   12±2   64±1.8   78±1.4   67±1.8 <0.001 
CO (l/min/m2)*    4±1.2  3.5±1.2  3.6±1.2  3.3±1.3  0.30 
SVR (WU.m2)   19±3.7   26±4   27±9.6   29±9.4 0.004† 
TAC (ml/mmHg. m2)*  0.56±1.4  0.61±1.3  0.59±1.3 0.53±1.3  0.71 
AoS (%)*   49±1.4   56±1.6   45±1.7   40±1.9   0.53 
AoC (cm2.mmHg-1.10-2)  3.4±1.1  3.4±1.2  3.2±1.2  2.9±1.4  0.81 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †-ANOVA Welch (W) test was used. Abbreviations: CKD=Chronic kidney disease, HD= Haemodialysis group, PD=Peritoneal 
dialysis group, SBP=Systolic blood pressure, DBP=Diastolic blood pressure, MBP=Mean blood pressure, PP=Pulse pressure, CO=Cardiac output, SVR=Systemic vascular resistance, TAC=Total arterial compliance, 
AoS=Ascending aortic strain, AoC=Ascending aortic compliance.  
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8.4.3 Cardiac structure and global function  
 
Left ventricular EDV and ESV were lower in the dialysis groups with the 
lowest seen in the PD patients (p<0.01). There was no significant LV 
hypertrophy in the dialysis groups (Table 8.4). There was also no difference in 
global systolic function, i.e. EF (Table 8.5).  
There was evidence of diastolic dysfunction (Table 8.5). The E/A ratio was 
significantly lower in dialysis patients (lowest E/A ratio seen in PD patients). 
However, the significance was lost after correcting for age and sex. There 
was also a trend towards increased IRT (p=0.09) and myocardial performance 
index (p=0.095), with the most marked changes seen in the PD cohort. 
 
8.4.4 Myocardial mechanics 
 
Radial and longitudinal systolic velocity was impaired in all CKD groups 
(p≤0.002). However, there was no apparent difference in systolic velocities 
between HD and pre-dialysis groups. Conversely, PD patients displayed the 
lowest radial and longitudinal systolic velocities (Table 8.6).  
Similarly, impairment in early radial and longitudinal relaxation was evident in 
the CKD groups (p≤0.003), with the most marked reduction seen in the PD 
cohort. There was no difference in late diastolic relaxation velocity (A’) 
between the groups. Consequently, longitudinal E’/A’ was reduced in both HD 
and PD groups (p≤0.003).  
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Table 8.4: Left ventricular structure assessment. 
 
 Controls 
n=10 
CKD stage 5 
n=10 
HD 
n=9 
PD 
n=8 
P-value 
LVEDV (ml/m2)* 76±1.2 64±1.1 66±1.2 52±1.2 <0.001 
LVESV (ml/m2)* 24±1.3 18±1.3 20±1.2 16±1.3 0.01 
LVSV (ml/m2) 52±6.9 45±6.2 46±8.7 36±5.4 <0.001 
LVMht2.7 (g/m2.7) 22±3.8 25±4.7 23±3.7 20±1.9 0.08 
RAA (cm2/m2) 12±1.9 11±1.2 12±1.4 10±2.3 0.078 
LAA (cm2/m2)* 12±1.3 11±1.2 12±1.2 11±1.3 0.61 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. Abbreviations: CKD=Chronic kidney disease, HD= Haemodialysis group, PD=Peritoneal 
dialysis group, LVEDV=Left ventricular end-diastolic volume, LVESV= Left ventricular end-systolic volume, LVSV= Left ventricular stroke volume, LVMht(2.7)=Left ventricular mass 
indexed to height to the power of 2.7, RAA=Right atrial area, LAA=Left atrial area.  
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Table 8.5: Left ventricular global systolic and diastolic function assessment. 
 Controls 
n=10 
CKD stage 5 
n=10 
HD 
n=9 
PD 
n=8 
P-value 
EF (%)*   67±1.1   71±1.1   69±1.1   68±1.1  0.67 
IRT (ms)   62±11   72±8.8   73±17   84±21 0.092† 
ICT (ms)   48±23   33±15   37±21   48±21  0.27 
Mitral E flow (mls)*   46±1.2   48±1.2   49±1.4   34±1.4 0.049 
Mitral A flow (mls)   20±4.2   23±3.5   24±6.4   22±3.6  0.28 
E/A ratio*  2.4±1.2  2.1±1.2  2.1±1.5  1.5±1.4 0.048 
ET (ms)  271±15  277±19  265±30  249±30  0.11 
Tei  0.41±0.1  0.38±0.085  0.43±0.16  0.54± 0.17 0.095 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. †-ANOVA Welch (W) test was used. Abbreviations: CKD=Chronic kidney disease, HD= 
Haemodialysis group, PD=Peritoneal dialysis group, EF=Ejection fraction, IRT=Isovolumic relaxation time, ICT=Isovolumic contraction time, E flow=Early diastolic flow, A flow=Late 
diastolic flow, ET=Ejection time, Tei=Myocardial performance index.  
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Table 8.6: Myocardial velocity assessment. 
 Controls 
n=10 
CKD stage 5 
n=10 
HD 
n=9 
PD 
n=8 
P-value 
Rad S’ (cm/s)  2.8±0.33  2.4±0.28  2.4±0.35  2.2±0.42 0.0078 
Rad E’ (cm/s)  4.4±0.57  3.3±0.52    3.0±0.63  2.9±0.52 <0.001 
Rad A’ (cm/s)*  1.4±1.3  1.2±1.3  1.2±1.4  1.3±1.3  0.54 
Long S’ (cm/s)*  4.8±1.3    3.0±1.5  2.9±1.4  2.8±1.2 0.002 
Long E’ (cm/s)  7.9±1.1  6.7±1.6  5.5±2.2  5.1±1.3 0.003 
Long A’ (cm/s)  2.1±0.5  2.6±0.72  2.5±0.99  2.6±0.76  0.45 
Long E’/A’ ratio  3.8±0.94  2.6±0.58  2.4±1.0  2.2±1.2 0.003 
Long E/E’ ratio  5.9±0.87  7.7± 2.7   10± 4.1  7.4±2.0 0.015 
Data presented as mean ± standard deviation. *- Logarithmic transformation was applied. Abbreviations: CKD=Chronic kidney disease, HD= Haemodialysis group, PD=Peritoneal 
dialysis group, Rad=Radial, Long=Longitudinal, S’=Peak systolic velocity, E’=Early diastolic velocity, A’=Late diastolic velocity, E’/A’=Ratio of E’ over A’, E/E’ ratio=Ratio of early 
diastolic mitral flow to early diastolic myocardial velocity. 
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In addition, E/E’, a surrogate marker of LV end-diastolic pressure, was 
elevated in the CKD groups. Notably, it was highest in the HD patients rather 
than in PD patients. All these differences remained significant even after 
adjusting for sex and age. 
 
8.4.5 Relationship between vascular & myocardial function 
 
Radial and longitudinal systolic and early diastolic velocities were all inversely 
related to BP (SBP, DBP and MBP), after adjusting for age and sex. There 
was also an inverse association between longitudinal E’/A’ ratio and BP, 
independent of age and sex. There was no association between longitudinal 
E/E’ ratio and BP.  
 
When only dialysis patients were included into the regression models, only the 
early relaxation velocities remained negatively associated with DBP and MBP. 
Longitudinal E’/A’ ratio was inversely associated with MBP but not to SBP or 
DBP. There were no significant associations between any other myocardial 
mechanics indices and BP. (Table 8.7).  
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Table 8.7: Relationship between blood pressure and myocardial mechanics.  
(Only dialysis population included into model, n=17) 
 
Models were adjusted for age, and sex. Abbreviations: Rad=Radial, Long=Longitudinal, E’=Early diastolic velocity, A’=Late diastolic velocity, DBP=Diastolic blood 
pressure, MBP=Mean blood pressure. 
 
  DBP   MBP  
 β-coefficient P-value Regression Model 
Adjusted-R2 
β-coefficient P-value Regression Model 
Adjusted-R2 
Rad E’ -16.7 0.001 0.63 -14.9 0.004 0.61 
Long E’ -5.25 0.001 0.68 -4.44 0.004 0.60 
Long E’/A’ ratio -5.88  0.07 0.36 -7.09 0.004 0.44 
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8.5 Discussion  
 
This is the first study to comprehensively assess associations between 
cardiovascular measures and dialysis in children using novel CMR 
sequences.  Our key findings were: i) SVR was elevated in both dialysis 
groups but was highest in peritoneal dialysis, ii) Systolic and diastolic 
impairment was evident in dialysis patients and was most marked in 
peritoneal dialysis, and iii) There was an independent and inverse relationship 
between DBP and MBP with myocardial diastolic function in children on 
dialysis.  
 
8.5.1 Vascular effects of dialysis 
 
Hypertension is common in children on long-term dialysis (127) and its 
determinants are multi-factorial. Volume overload is undoubtedly an important 
factor (128, 129). Its contribution to high BP will vary at different times due to 
wide fluctuations in intravascular volume between dialysis sessions (129). 
Other key factors are thought to be arterial stiffness (i.e. low arterial 
compliance) and elevated SVR (13). However, their relative significance is 
unclear in the dialysis population. In order to determine this, the children were 
studied after dialysis in this study. To the best of my knowledge, this study is 
the first to simultaneously assess the key determinants of BP in a paediatric 
dialysis cohort using CMR.  
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As expected, preload was decreased in both dialysis cohorts, indicated by 
reduced EDV and SV. This was most marked in PD patients as they had a 
dwell volume in the peritoneum causing increase intra-abdominal pressure, in 
turn leading to reduced preload from reduced venous return (130). Despite 
that, elevated BP was present in HD and PD patients. Neither cardiac output 
nor aortic compliance was abnormal, indicating that volume overload and 
arterial stiffness were not important factors in the post-dialytic setting. Instead, 
an increased SVR was the only significant finding in both groups. This 
suggests that SVR may be the most likely explanation for elevated BP post-
dialysis.  
 
However, there are two caveats to this statement. Firstly, there are other 
methods to assess arterial stiffness apart from TAC. Numerous studies have 
documented abnormal stiffness in paediatric dialysis population using pulse 
wave velocity (45, 131, 132). As this was not recorded in this study, arterial 
stiffness may be present on PWV measurement and could be an important 
determinant of hypertension.  
 
Secondly, vascular stiffness and SVR are dependent on loading conditions. 
Arterial stiffness is known to be increased in fluid overloaded dialysis patients 
(123, 133). The viscoelastic properties of arterial walls are such that the 
vessels become stiffer as they stretch. However, a low preload may be 
associated with increased SVR (86). It is likely that dialysis children in this 
study had a low preload as indicated by reduced EDV. If the children had 
been scanned before their dialysis session and were in an “overloaded” state, 
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abnormal TAC may have been a more prominent feature. Indeed, arterial 
stiffness may play a more important role in “overloaded” patients who are 
hypertensive before their dialysis session. This will need to be investigated in 
future studies. 
 
In healthy individuals, afterload increases (i.e. vasoconstriction) to maintain 
‘normal’ physiological blood pressure in a low preload state. The dialysis 
patients in this study had low preload, high SVR but an elevated BP, instead 
of ‘normal’ BP. This may reflect a resetting of baroreceptor reflex as seen in 
chronic essential hypertension (134). Nonetheless, my findings highlight that 
in children post-dialysis, raised SVR appears to be the key contributor to 
increased afterload and BP.  
 
It is well recognised that there is a subset of haemodialysis patients that 
experience intra- or post-dialytic hypertension (135). This is associated with a 
worse CV mortality (136). Although the reasons for this are not known, its 
pathogenesis is thought to be complex and include mechanisms like 
sympathetic overactivity, renin-angiotensin system activation, endothelial 
dysfunction, and clearance of anti-hypertensive medications leading to 
increased vasoconstriction post-dialysis (135). The HD patients in this study 
do not fulfil the criteria for post-dialytic hypertension. Nevertheless, the 
observation of elevated post-dialysis BP (compared to controls) and raised 
SVR in these children is consistent with above mechanisms and may 
represent a “pre-hypertensive” phenotype. Further research is needed to 
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investigate how or if underlying elevation in SVR may lead to subsequent 
development of post-dialytic hypertension in haemodialysis. 
 
Interestingly, the greatest SVR was observed in peritoneal dialysis. This 
finding is in keeping with other studies that used different methodologies and 
also demonstrated increased SVR in peritoneal dialysis (137, 138). Blood 
pressure and SVR has been shown to acutely rise on instillation of PD fluid. 
The exact cause for this is unclear. However, several explanations have been 
proposed such as, impaired baroreceptor sensitivity associated with 
instillation of glucose containing peritoneal dialysate fluid (139), compression 
of mesenteric vessels secondary to filling of the peritoneal cavity and the 
cooling effect of the dialysate fluid inducing mesenteric vasoconstriction (140). 
The PD patients were all scanned more than three hours after instillation of 
PD fluid. Any acute cooling effect arising from instillation of dialysate fluid 
would be negligible. The daytime dwell consisted of icodextrin containing 
dialysate in all patients, rather than glucose containing fluid. While glucose 
containing dialysates can cause impaired baroreceptor response, icodextrin 
dialysates have less of an effect as it is “glucose-sparing” and does not 
induced the hyperglycaemic and hyperinsulinaemic response thought to be 
responsible (141). Hence, I believe the most likely cause of raised SVR in PD 
is the compression effect of peritoneal dialysate fluid on the mesenteric 
arteries. Indeed, an increase in dialysate dwell volume has been 
demonstrated to be significantly associated with an increase in SVR (142). 
The presence of a dwell volume in situ throughout the day may mean that PD 
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patients are subjected to greater afterload for a prolonged duration. This in 
turn may contribute to adverse consequences on the myocardium.  
 
8.5.2 Association between dialysis and myocardial measures 
 
The finding of sub-clinical systolic and diastolic impairment is consistent with 
previous ECHO studies in both adults (143-145) and paediatric (146, 147) 
dialysis populations. This study confirms that subtle myocardial impairment is 
present in children on dialysis despite the absence of traditional 
cardiovascular risk factors typically seen in adults.  
 
Reduced longitudinal systolic function is often the first indicator of sub-clinical 
impairment and may be accompanied by compensatory increase in radial 
function to preserve global LV function (121). In this study, both longitudinal 
and radial systolic mechanics were reduced in dialysis patients but EF 
remained preserved. This suggests impairment of myocardial mechanics in 
dialysis may be counteracted by other compensatory mechanisms in order to 
maintain global function. It is unclear from this study what these mechanisms 
are. However, one possibility is the compensatory increase in LV rotational 
function, which has been observed in patients with heart failure with 
preserved ejection fraction (148). This is worth investigating further in future 
studies. 
  
Notably, myocardial impairment was most marked in the PD patients. This is 
slightly surprising as peritoneal dialysis is widely believed to have theoretical 
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advantages compared with HD, such as superior haemodynamic stability from 
continuous fluid removal, better clearance of medium sized uraemic toxins 
and less systemic inflammation (140, 149). Peritoneal dialysis also does not 
result in myocardial stunning due to the absence of intra-dialytic hypotension 
(150). In contrast, haemodialysis induces transient myocardial ischaemia 
through various mechanisms such as HD related hypotension and 
ultrafiltration related factors (151). The HD cohort in this study had also been 
receiving dialysis for a longer duration than the PD cohort, which meant 
greater exposure to repeated intra-dialytic ischaemic insults. Despite this, 
myocardial function appeared comparatively worse in PD patients. Part of this 
may be explained by the recovery of LV function in the HD cohort by the time 
of CMR scan. Myocardial stunning largely resolves within 30 minutes after 
dialysis (152, 153). This means LV function would have had sufficient time to 
recover back to baseline as CMR was performed one-hour post 
haemodialysis.  
 
My findings suggest that the effect of increased afterload on the myocardium 
may be an important factor in dialysis related LV impairment, particularly in 
peritoneal dialysis. Previous studies have found that afterload (including both 
non-pulsatile and pulsatile components, measured by SVR and PWV 
respectively) is inversely related to myocardial function. This has been shown 
in hypertensive adults (125) and in larger cohorts such as the Framingham 
Heart Study (154). This study is the first to demonstrate a significant 
relationship between impaired LV relaxation and diastolic (and mean) blood 
pressure in children on dialysis. Thus, it is perhaps unsurprising that SVR was 
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greatest in the PD cohort while diastolic (and systolic) function was also the 
lowest. 
 
However, it is important to point out that myocardial velocity, like SVR and BP, 
is preload dependent. This means that preload may be an important 
confounder in this relationship. Indeed, a low preload can be associated with 
reduced E’ (155) and increased afterload (86) (Figure 8.1). More research is 
needed to understand how different preload conditions may affect the 
relationship between afterload and myocardial function. This study only 
looked at the relationship at a single time point (i.e. post-dialysis). Future work 
examining how this relationship changes during haemodialysis or with 
different dwell volumes in PD patients may be useful.  
 
The acute effects of dialysis on the CV system have been relatively well 
described. Conversely, the long-term CV impact of these changes remains 
unclear. Survival differences between haemodialysis and peritoneal dialysis 
have been difficult to determine as different studies have produced conflicting 
results (156). Nonetheless, there is a general consensus PD survival is 
broadly similar to HD in the long-term (157, 158). The present findings 
suggest that the short-term effects of PD on the CV system may not be as 
benign as currently believed. Future studies are needed to examine if 
chronically increased afterload may translate to CV changes and increased 
long-term risk in peritoneal dialysis.  
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Figure 8.1: Confounding effect of preload: Is there a significant 
relationship between E' and afterload (Blood pressure/systemic vascular 
resistance), independent of pre-load? Abbreviations: E’=early diastolic 
myocardial velocity.  
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8.6 Limitations 
 
The main limitation is the relatively small number of dialysis patients recruited 
into the study. Recruitment of these children was difficult. Given the rarity of 
paediatric end stage renal failure, there was a limited population of children 
available for recruitment in a single centre study. Furthermore, the high 
psychosocial and care burden associated with their condition meant that 
many of the children and families were reluctant to take part in research that 
required more hospital visits. In order to overcome that, we minimised 
inconvenience to patients by organising the CMR to coincide with outpatient 
appointments (in PD and pre-dialysis patients) and after their in-hospital 
dialysis sessions for HD patients. Despite the small numbers recruited, we 
were able to show differences in cardiovascular indices between the groups 
(although this study was not adequately powered to make a direct post-hoc 
comparison between dialysis modalities). Future studies will require multi-
centre recruitment in order to increase study numbers.  
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8.7 Conclusion 
 
In this study, I have found that elevated SVR and myocardial impairment is 
present in children on dialysis. Furthermore, SVR may be associated with 
myocardial impairment.  Future studies are needed to investigate how 
vascular properties may vary between dialysis sessions as loading conditions 
changes. In addition, further investigation into how this in turn affects 
myocardial function is also required to better understand the impact of dialysis 
on myocardial function. 
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9 Conclusion and future work 
 
9.1 Summary 
 
Efforts to reduce cardiovascular risk in paediatric CKD have had minimal 
success over the past few decades. Identifying high-risk patients is difficult as 
conventional methods of cardiovascular assessment have limitations. 
Cardiovascular magnetic resonance imaging has numerous advantages and 
may be a more valuable tool for clinical assessment in this population. In this 
thesis, I investigated the utility of CMR for the cardiovascular phenotyping of 
pre-dialysis CKD in children. In addition, I also conducted two smaller 
exploratory studies on dialysis and renovascular hypertension children.  
 
Using CMR, I was able to elicit clinically important findings in children with 
renal disease. Importantly, it did not require the use of MRI contrast, which is 
both unpleasant for children and contraindicated in CKD. The combination of 
sensitivity of novel CMR techniques like tissue phase mapping with precision 
of conventional sequences has made it an effective tool for the detection of 
subtle abnormalities. The other key advantage of the sequences used is the 
speed of acquisition. This enabled comprehensive cardiovascular assessment 
to be performed swiftly. All of this together helped improve the overall patient 
experience and made it a much more tolerable investigation for children.  
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9.2 Myocardial abnormalities in paediatric renal disease 
 
A key aspect of this study was the novel detection of sub-clinical systolic and 
diastolic impairment with CMR. The ability to measure radial and longitudinal 
function allowed a detailed assessment of uraemic cardiomyopathy. Future 
studies should investigate how impairment in myocardial mechanics may 
evolve with disease progression. Larger studies are also needed to confirm 
the findings of this small exploratory study on dialysis patients. Examining 
how these parameters may change in dialysis may be helpful for a better 
understanding of the acute effect of haemodialysis on myocardial mechanics. 
This may help to improve current management of dialysis related 
complications such as myocardial ischaemic insults secondary to intra-dialytic 
hypotension. 
 
Abnormalities in radial and longitudinal myocardial velocity are likely to be an 
early manifestation of myocardial involvement, as they appear to precede the 
development of LVH. Thus, myocardial velocity measured with tissue phase 
mapping may have a role as a potential imaging biomarker in the future. At 
present, there are no established normative values for myocardial velocity in 
children. This will need to be established. In the future, large prospective 
studies with long-term follow up are required to determine the prognostic 
significance of these indices and its ability to predict cardiovascular risk. 
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9.3 Role of systemic vascular resistance in hypertension in CKD 
 
Although the mechanism for hypertension in CKD is multi-factorial, arterial 
stiffness is widely believed to be the key component in paediatric CKD. 
Previous studies have found evidence of increased arterial stiffness, which is 
consistent with the calcium and phosphate dysregulation and vascular 
remodelling so frequently seen in this population. Nonetheless, the role of 
arterial stiffness in the pathogenesis of hypertension is uncertain, even though 
it may be present. In this thesis, I have shown that it is possible to assess the 
key components of hypertension simultaneously using CMR in order to 
determine their relative importance.  
 
Systemic vascular resistance appears to be the most important determinant of 
hypertension in renal disease in children. This suggests that treatment 
resistant hypertension in paediatric CKD or renovascular hypertension may be 
due to a significantly elevated SVR. Further investigation is needed to confirm 
this. If so, hypertension treatment in this population may be further optimised 
by therapies that reduce SVR, such as systemic vasodilators. Furthermore, 
SVR, measured by CMR, may also serve as a potential target to guide 
management of patients, particularly in resistant hypertension.  
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Although the dialysis study was exploratory in nature and the numbers were 
small, the markedly elevated SVR and its association with diastolic 
dysfunction in peritoneal dialysis were particularly interesting. My findings 
suggest that the daytime dwell volume may be an important factor, but 
preload may also be a confounding factor. Larger studies are needed to better 
understand how preload can affect SVR and if this may have any significant 
long-term consequences on the myocardium. If so, more work needs to be 
done to look at how this can be mitigated (such as studying if changing dwell 
volumes may reduce SVR).  
 
The investigations in this thesis were limited to a cross-sectional evaluation of 
the determinants of hypertension at a single time point. However, these 
haemodynamic factors may change as the disease progresses, not least due 
to fluid accumulation in end stage disease. Understanding how this may 
evolve will allow clinicians to better tailor treatment to patients at different 
disease stages.  
 
There are many different causes of elevated SVR in CKD. The relative 
significance of these mechanisms is uncertain. Future studies may combine 
CMR haemodynamic measures with other biomarkers (e.g. neurohumoral) to 
better understand the pathogenesis of raised SVR in CKD and renovascular 
hypertension. This may be useful for designing future therapies to effectively 
target key pathological mechanisms at a biochemical level.  
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The effect of aortic compliance on blood pressure does not appear to be 
important in paediatric renal disease. Nonetheless, the influence of arterial 
stiffness on afterload cannot be discounted. In fact, characteristic impedance 
is one of the key elements determining blood pressure (the other two being 
SVR and arterial compliance in the 3-element Windkessel model (85)). There 
is increasing recognition that arterial impedance, i.e. resistance to oscillatory 
flow, is an important factor in hypertension (159). Thus, methods for 
impedance analysis such as pulse wave velocity measurement will continue 
to be an important part of cardiovascular assessment. New CMR protocols 
have been developed that allow PWV measurements and have been used to 
demonstrate abnormal vascular function following coarctation of aorta repair 
(160). Future studies may incorporate this protocol to provide an even more 
comprehensive evaluation of vascular function in paediatric CKD. 
 
9.4 Conclusion 
 
In conclusion, CMR is a useful tool for the cardiovascular assessment of 
children with renal disease. The unique findings of vascular dysfunction and 
sub-clinical myocardial impairment in paediatric renal disease using CMR 
have clinically significant implications. Future studies are needed to determine 
the prognostic significance of these abnormalities and to evaluate its utility as 
potential imaging biomarkers.   
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